



B|B Bellevue

Asset Management

Bellevue Funds (Lux)

A SICAV according to Luxembourg law

Prospectus

April 2019

Subscriptions will only be accepted on the basis of the last valid Prospectus or the last valid Key Investor Information Document (“KIID”) in connection with the (i) last published Annual Report of the Company or (ii) the last published Semi-annual Report of the Company, if published later than the Annual Report. Other information than that contained in this Prospectus or in the KIID may not be given.

The Management Company, MDO Management Company S.A., and the Board of Directors of the Bellevue Funds (Lux) SICAV hereby inform investors that they may only directly exercise their full legal rights as investors with regard to Bellevue Funds (Lux) SICAV, namely their right to participate in the shareholder meetings, if they are registered in the shareholder register of the Company in their own name and on their own account. In case that an investor has subscribed in shares of the Company via a Nominee, which has executed the subscription in its own name, but on the account of the investor, the investor may not – partly or fully – claim all of his investor rights against Bellevue Funds (Lux) SICAV anymore.

Investors are advised to inform themselves about their rights.

TABLE OF CONTENTS

1.	INTRODUCTION	4
2.	ORGANISATION	6
3.	STRUCTURE OF THE FUND MANAGEMENT AND ADMINISTRATION	7
3.1	Company	7
3.2	Custodian	9
3.3	Management Company, central administrator, domiciliary and principal paying agent	10
3.4	Registrar	11
3.5	Investment Manager	11
3.6	Auditor of annual report	11
4.	SHARES	11
4.1	Description of Shares	11
4.2	General notes on the subscription, redemption and switching of Shares	13
4.3	Calculating the net asset value	16
4.4	Valuation date.....	18
4.5	Suspending calculation of the net asset value, the issue, the redemption and the exchange of shares	18
4.6	Fees and costs	19
5.	INVESTMENTS	20
5.1	Investments of the company	20
5.2	Investor profile.....	21
5.3	Investment restrictions	22
5.4	Investment techniques and financial instruments	27
5.5	General notes on risk	31
6.	LEGAL MATTERS.....	38
6.1	Tax situation.....	38
6.2	Annual General Meeting and Reporting	40

6.3	Applicable Law, Place of Jurisdiction	40
6.4	Documents for inspection	40
6.5	Data Protection	41
6.6	Use of benchmarks.....	42
7.	MARKETING	42
	ANNEX I: SPECIAL SECTION	44
1.	BELLEVUE FUNDS (LUX) - BB ADAMANT BIOTECH.....	44
2.	BELLEVUE FUNDS (LUX) - BB ADAMANT MEDTECH & SERVICES.....	46
3.	BELLEVUE FUNDS (LUX) - BB ADAMANT DIGITAL HEALTH.....	48
4.	BELLEVUE FUNDS (LUX) - BB ADAMANT HEALTHCARE INDEX	50
5.	BELLEVUE FUNDS (LUX) - BB ADAMANT EMERGING MARKETS HEALTHCARE	52
6.	BELLEVUE FUNDS (LUX) - BB ADAMANT ASIA PACIFIC HEALTHCARE.....	55
7.	BELLEVUE FUNDS (LUX) - BB ADAMANT SUSTAINABLE HEALTHCARE.....	58
8.	BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR EUROPE.....	61
9.	BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR EUROPE SMALL	63
10.	BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR SWISS SMALL&MID.....	66
11.	BELLEVUE FUNDS (LUX) - BB AFRICAN OPPORTUNITIES.....	68
12.	BELLEVUE FUNDS (LUX) - BB GLOBAL MACRO	71
13.	BELLEVUE FUNDS (LUX) – BB EUROPE EQUITY MARKET NEUTRAL.....	75

1. INTRODUCTION

Bellevue Funds (Lux) (the "Company") is organised as an investment company with variable capital "*société à capital variable*" (SICAV) under the current version of the Law of the Grand Duchy of Luxembourg of 10 August 1915 on commercial companies ("Law of 1915") and is authorised under Part I of the Law of 17 December 2010 relating to undertakings for collective investment ("Law of 2010") as an undertaking for collective investment (UCITS).

The Company is structured as an umbrella fund, which means that various Sub-funds ("Sub-funds") can be created from time to time that reflect different investment portfolios, and that can be issued in different share classes. The shares of the Sub-funds will be offered for subscription via the different distribution partners as outlined in the Special Section of this Prospectus. The Company may appoint, under the supervision of its Board of Directors, one or more asset managers as investment advisor for one or more of its Sub-funds.

This Prospectus is divided into a General Part (Chapter 1–7), which contains the information applicable for all Sub-funds, and into a Special Section, which describes the various Sub-funds and their characteristics. The Prospectus further includes an annex with information for foreign investors. The overall Prospectus includes in the Special Section all Sub-funds and may be perused by the investors at the domicile of the company. The prospectus may be changed or modified at any time. The investors shall be informed hereof respectively.

The Board of Directors is authorised to issue units with no par value ("units", "shares") in relation to the sub-funds described in the Special Part, whereby, as noted in the Chapter "Description of the Units" and/or in the Special Part, both distributing units and reinvesting units ("unit categories") may be issued for each sub-fund. The Company may issue Share classes with inter alia different minimum investments, dividend policies, currencies and fee structures. The respective Share classes issued in a Sub-fund are defined in the relevant Supplement of the Sub-fund in question. The distribution of Shares in a certain Sub-fund or Share class may be limited to certain countries.

According to the Law of 2010, the Company is also authorized to produce one or more Prospectus versions for the distribution of shares of one or more Sub-funds for a particular distribution country. These particular prospectuses always contain the General Part and the respective Special Section of the Prospectus. They may further contain the relevant information for the various distribution countries, in which the respective sub-funds are registered for public distribution.

The issue of Shares takes place at prices quoted in the currency of denomination of the Sub-fund or the respective share-class in question. As described in section 4.1, a subscription fee may be charged. Details of the subscription period and the terms and conditions for the initial issue of each Sub-fund are given in the relevant Special Section. The Special Section may allow for the possibility of the initial subscription to be made through a total or partial contribution in kind. However, the composition of such contribution in kind must be consistent with the investment limits contained in the general part as well as with the investment objectives and investment policy described in the Special Section of the Sub-fund in question. With regard to the contribution in kind, the auditor of the Company has to produce a special audit report.

The Company may issue Shares in new, additional Sub-funds at any time. The complete Prospectus and, where applicable, the relevant Special Sections will be amended accordingly.

Shares may be redeemed at a price described in the subsection "Redemption" in the section "General Notes on the Subscription, Redemption and Switching of Shares".

Subscriptions may only be accepted based on the valid Prospectus or the valid KIID in conjunction with the (i) most recent annual report or (ii) the most recent semi-annual report of the Company, where this is published after the annual report.

The Shares may be offered on the basis of the information and descriptions of this Prospectus. No information other than that contained in this Prospectus or in the simplified prospectus may be given.

This Prospectus, the special sections and the KIID do not constitute an offer or advertisement in those jurisdictions where such an offer or advertisement is prohibited, or in which persons making such offer or advertisement are not authorised to do so, or in which the law is infringed if persons receive such offer or advertisement.

Potential investors should inform themselves about the relevant foreign exchange regulations and about the applicable and relevant legal and tax implications.

The information in this Prospectus, in each KIID and in each Special Section is in accordance with the current law and rules and regulations of the Grand Duchy of Luxembourg, and is thus subject to alterations.

Information in this Prospectus in “Swiss Francs” or “CHF” relate to the currency of Switzerland; “US Dollars” or “USD” relate to the currency of the United States of America and “Euro” or “EUR” relate to the currency of the European Monetary Union.

As the Company’s units are not registered in the United States under the United States Securities Act of 1933, they may not be offered or sold, either directly or indirectly to US persons, unless such offer or sale is made possible by an exemption from registration under the United States Securities Act of 1933.

In addition, the Company seeks to remain in compliance with US FATCA regulations at all times. This compliance can be achieved by adopting different statuses, as provided for in the FATCA provisions. Moreover, the Company hereby confirms that it will become a participating FFI in accordance with the FATCA regulations and that it will be registered accordingly and will be able to provide proshareits compliance with FATCA and will request a GIIN and, in addition, will do business only with professional financial intermediaries who are properly registered and have received a GIIN.

Taking into account the restriction on distribution to US persons, the eligible investors for the purposes of the FATCA provisions are the following: (i) *exempt beneficial owners*, (ii) *active non-financial foreign entities* (“active NFFEs”), (iii) US persons who do not qualify as a *specified US persons*, and (iv) *financial institutions* which are not *non-participating financial institutions*.

However, it cannot be ruled out that the Company will change or give up this status in the future. It is recommended that potential and existing investors contact their advisers if they have any questions about the current FATCA status of the Company.

If the Company is obligated to pay a withholding tax or to file a report or suffers other damages due to the lack of FATCA compliance of an investor, the Company reserves the right to make claims for damages against the relevant investor, without prejudice to other rights.

2. ORGANISATION

The registered office of the Company is in Centre Etoile, 11-13 Boulevard de la Foire, L-1528 Luxembourg.

Board of Directors of the Company

Chairman

André Rüegg, CEO Bellevue Group AG, Küsnacht, Switzerland

Members of the Board

Martin Vogel, CEO MDO Services S.A., Luxembourg, Grand Duchy of Luxembourg.

Patrick Fischli, Head of Sales Bellevue Asset Management AG, Küsnacht, Switzerland

Daniel Sigg, Board Member of the Bellevue Group AG, Küsnacht, Switzerland

Jean-Francois Schock, President and Founder of JEFFIX Concept sprl, Brussels, Belgium

Management Company

MDO Management Company S.A., 19, rue de Bitbourg,
L-1273 Luxembourg

Board Member of the Management Company

Chairman

Géry Daeninck, Independent Director

Members of the Board/

Martin Vogel, CEO, MDO Services S.A., Luxembourg

Yves Wagner, Independent Director

Carlo Montagna, Independent Director

John Li, Independent Director

Custodian

RBC Investor Services Bank S.A.
14, Porte de France
L-4360 Esch-sur-Alzette

Central Administration, Principal Paying Agent, Transfer Agent, Domiciliary Agent and Listing Agent

RBC Investor Services Bank S.A.
14, Porte de France
L-4360 Esch-sur-Alzette

Distributors

The Company or the Management Company, respectively, has authorized some distribution partners and may appoint additional distribution partners, which offer shares in one or the other jurisdiction.

Auditor of the Company

PricewaterhouseCoopers société coopérative
2, Rue Gerhard Mercator
L-2182 Luxembourg

3. STRUCTURE OF THE FUND MANAGEMENT AND ADMINISTRATION

3.1 COMPANY

The Company is a "*société d'investissement à capital variable*" (SICAV) in the Grand Duchy of Luxembourg under the current version of the 2010 Law. The Company is authorized to perform collective investments in transferable securities and other liquid financial assets under Part I of the 2010 Law. The Company was incorporated on 26 March 2009 for an unlimited period. The minimal capital of the company is Euro 1,250,000.

In the event that the capital of the Company falls below two thirds of the minimum capital laid down by law, the Board of Directors of the Company is required to submit the question of liquidation of the Company to a general meeting within forty (40) days. The general meeting may resolve the question of liquidation with a simple majority of the investors present/represented (no quorum is required).

In the event that the capital of the Company falls below one-fourth of the minimum capital laid down by law, the Board of Directors of the Company is required to submit the question of liquidation of the Company to a general meeting, which must be called within the same period. In this case, a liquidation may be resolved by one-fourth of the votes of the investors present/represented at the general meeting (no quorum is required).

The Articles contain no provisions with regard to the remuneration (including pensions and other benefits) of the Board of Directors. The expenses of the Board of Directors are paid. Remuneration must be approved by the investors in the general meeting.

The Company is registered with the Luxembourg Trade and Companies Register under B 145566. The Articles may be consulted and sent out on request. It was published in Luxembourg in the *Mémorial C, Recueil des Sociétés et Associations* ("*Mémorial*") on 14 April 2009, and most recently on 10 December 2012. The registered office of the Company is 11-13, boulevard de la Foire, L-1528 Luxembourg.

The Company is liable to third parties in respect of the liabilities of the relevant sub-fund only. Also in the relationships with the investors among each other, each sub-fund shall be treated as an autonomous entity and the liabilities of each sub-fund shall be applied to it when calculating the net asset value.

The Board of Directors of the Company is shown in the "*Organisation*" section. The Company is managed by the Board of Directors.

LIQUIDATION OF THE COMPANY AND ITS SUB-FUNDS

The Company may be liquidated at any time by a shareholders meeting subject to the legally foreseen quorums of shareholder and share presences.

If the total net assets of the Company fall below 2/3 or 1/4 of the required minimum capital, the Board of Directors will put the question whether to liquidate the Company to a shareholders meeting. If the Company shall be liquidated, the liquidation shall be executed by one or more liquidators. These shall be appointed by a shareholders meeting, which shall also decide on their competencies and remuneration. The liquidators will liquidate the Company's assets in the best interest of the shareholders and will distribute the net proceeds of the sub-funds to the respective shareholders of the sub-funds or its share classes. Net liquidation proceeds, that cannot be distributed to shareholders after the liquidation has been terminated, will be deposited with the "*Caisse de Consignation*" in Luxembourg until the term of limitation has passed.

The dissolution and liquidation of sub-funds with a pre-defined term will be done automatically after the respective term has passed.

If the total net asset value of a Sub-fund or of a share class within a Sub-fund has fallen below a value or has not reached a value, which is required for an economically efficient management of that Sub-fund or of this share class, or in

the event of a substantial change in the political, economic and monetary environment, or as part of a rationalization, the Company may decide to redeem and cancel all shares of the corresponding share class(es) at the net asset value (taking into account the actual realization prices and realization cost of the investments) as per the valuation day or as per the date on which the decision takes effect.

Notwithstanding the powers of the Board of Directors, a shareholders' meeting of a Sub-fund may – based on a proposal by the Board of Directors – decide to reduce the Company's capital by cancelling issued shares in this sub-fund and repaying the net asset value of the shares to the shareholders. In this case, the net asset value is calculated on the day at which the decision comes into effect, taking into consideration the realized prices when selling the assets and all costs related in this connection.

The shareholders of the respective Sub-fund shall be informed of the decision by the shareholders' meeting or by the Board of Directors to take back and cancel the shares via a publication of this resolution in the "Mémorial" and in one Luxembourg daily newspaper and, if necessary, in the official publication means in the various distribution countries. The counter value of cancelled shares that could not be distributed to shareholders, will be deposited with the "Caisse de Consignation" in Luxembourg until the term of limitation has passed.

**MERGER OF THE COMPANY OR OF SUB-FUNDS WITH ANOTHER COLLECTIVE INVESTMENT SCHEME ("UCI") OR WITH ITS SUB-FUNDS;
MERGER OF SUB-FUNDS**

"Mergers" are transactions, in which

- a) One or more UCITS or Sub-funds of such UCITS, the "absorbed UCITS", upon whose winding up without liquidation transfers all assets and all liabilities to another existing UCITS or Sub-fund of that UCITS, the "absorbing" UCITS", and whose shareholders receive in return shares in the absorbing UCITS and, if applicable, a cash payment not exceeding 10% of the net asset value of such units;
- b) two or more UCITS or Sub-funds of such UCITS, the "absorbed UCITS", upon whose winding up without liquidation transfers all assets and liabilities to another UCITS or Sub-fund of that UCITS formed by it, the "absorbing UCITS", and whose shareholders receive in return shares in the absorbing UCITS and, if applicable, a cash payment not exceeding 10% of the net asset value of such shares;
- c) one or more UCITS or Sub-funds of such UCITS, the "absorbed UCITS", that continue to exist until the liabilities have been paid off, transfers its net assets to another Sub-fund of the same UCITS, to another UCITS formed by it or to another existing UCITS or a Sub-fund of that UCITS, the "absorbing UCITS".

Mergers may only take place in accordance with the requirements regarding the form, procedures and information set out by the Law of 2010. The legal consequences of a merger are regulated in the Law of 2010.

Under the conditions described in the section "Liquidation of the Company and its Sub-funds", the Board of Directors may decide to allocate the assets of a Sub-fund or of a share class of a Sub-fund to another existing Sub-fund or share class of a Sub-fund or to another UCI pursuant to Part I of the Law of 2010 or to a foreign UCITS pursuant to the provisions of the Law of 2010 and the re-designation of the shares of the Sub-fund(s) or share classes in question as shares of another Sub-fund or of another share class (as a result of the scission or consolidation, if necessary, and through the payment of an amount that corresponds to the pro rata entitlement of the shareholders). Notwithstanding the competencies of the Board of Directors as described here above, the decision of a fund merger, as described herein, may also be taken by a shareholder meeting of the respective Sub-fund.

If the merger of a sub-fund results in the liquidation of the Company, the merger must be approved by the Annual General Meeting of Shareholders.

The shareholders shall be informed of any such decision in accordance with the following provisions and according to the relevant provisions contained in the Law of 2010, as well as any implementing regulations. The concerned shareholders are - during 30 days after the publication of this resolution - entitled to ask for the full and/or

partial redemption of their shares to the net asset value as defined in the section "Redemption of shares" and without paying any redemption commission or any other administrative fee. Shares that have not been redeemed will be switched on the basis of the net asset value of the respective Sub-funds of the day, on which the resolution came into effect. In the event of the allocation of units of an investment fund in the legal form of a "*fonds commun de placement*", the decision is binding only for shareholders who voted in favour of the allocation.

SHAREHOLDER MEETING OF THE COMPANY OR THE SHAREHOLDERS OF THE RESPECTIVE SUB-FUND

For the liquidation as well as for the merger of Sub-funds, the respective shareholder meetings of the Company and of its Sub-funds do not require any special quorum regarding the presence of the number of shares or the capital represented, and the decision may be taken with a simple majority of the shares present or represented at such shareholder meeting of the Company or the Sub-fund(s).

3.2 CUSTODIAN

The Company has appointed RBC Investor Services Bank S.A. ("RBC"), with registered office at 14, Porte de France, L-4360 Esch-sur-Alzette, Grand Duchy of Luxembourg, as depositary bank and principal paying agent (the "Depositary Bank"), with responsibility for

- (a) the custody of assets,
- (b) monitoring obligations,
- (c) cash flow monitoring

in accordance with the legal provisions and the Depositary Bank and Principal Paying Agent Agreement dated 24 June 2016, concluded between the Company and RBC (the "Depositary Bank and Principal Paying Agent Agreement").

RBC is registered in the Trade and Companies Register of Luxembourg (RCS) under the number B-47192 and was established in 1994 under the name "First European Transfer Agent". RBC holds a banking license in accordance with the provisions of the Luxembourg law of 5 April 1993 on the financial sector and specialises in depositary bank administration, fund accounting and related services. As at 31 October 2016, the equity amounted to EUR 1,059,950,131.

The Depositary Bank has been authorised by the Company to delegate its custody obligations (i) to agents in respect of other assets and (ii) to sub-custodians in respect of financial instruments, and to open accounts at such sub-custodians.

A current description of the custody obligations delegated by the Depositary Bank as well as a current list of all agents and sub-custodians is available upon request from the Depositary Bank or at the following link: <http://gmi.rbcits.com/rt/gss.nsf/Royal+Trust+Updates+Mini/53A7E8D6A49C9AA285257FA8004999BF>

In the performance of its obligations under the legal provisions and the Depositary Bank and Principal Paying Agent Agreement, the Depositary Bank is to act honestly, fairly, professionally, independently and exclusively in the interests of the Company and its shareholders.

On the basis of its monitoring obligations, the Depositary Bank shall:

- Ensure that the sale, issue, redemption, disbursement and cancellation of shares conducted on behalf of the Company are carried out in accordance with the legal provisions and the articles of association of the Company;
- Ensure that the value of the shares is calculated in accordance with the legal provisions and the articles of association;
- Act in accordance with the instructions of the Company or the Management Company acting in the name of the Company, unless such instructions violate legal provisions or the articles of association of the Company;
- Ensure that in the case of transactions relating to the Company's assets, the equivalent value is paid or transferred to it within the usual time limits;

- Ensure that the income of the Company is used in accordance with the legal provisions or the articles of association of the Company.

The Depositary Bank shall also ensure that the cash flows are properly monitored in accordance with the legal requirements and the Depositary Bank and Principal Paying Agent Agreement.

Conflicts of interest of the Depositary Bank

From time to time, conflicts of interest may arise between the Depositary Bank and the agents; for example, if an agent that has been appointed is a subsidiary which provides other custody services for the company for remuneration. On the basis of the applicable laws and regulations, the Depositary Bank continuously investigates potential conflicts of interest that may arise during the exercise of its functions. Any potential conflict of interest identified shall be treated in accordance with RBC's policy on conflicts of interest, which in turn is subject to the applicable laws and regulations for financial institutions in accordance with the Luxembourg law of 5 April 1993 on the financial sector.

Furthermore, potential conflicts of interest may arise when services are provided by the Depositary Bank and/or its subsidiaries to the Company, the Management Company and/or other parties. For example, the Depositary Bank and/or its subsidiaries may act as custodian, depositary bank and/or administrator for other funds. It is therefore possible that, in the conduct of the Depositary Bank's business, conflicts of interest or potential conflicts of interest may arise between the Depositary Bank (or one of its subsidiaries) and the Company, the Management Company and/or other funds for which the Depositary Bank (or one of its subsidiaries) acts.

RBC has introduced a policy on conflicts of interest with the aim of:

- identifying and analysing situations that could potentially involve a conflict of interests;
- identifying, acting on and monitoring conflicts of interest;
 - subdividing functions and hierarchies to ensure that business activities are carried out independently of the duties of the Depositary Bank;
 - implementing preventive measures to avoid any activity that could potentially lead to conflicts of interest such as:
 - RBC and any third party to whom depositary bank functions have been delegated shall reject any commission as investment manager.
 - RBC shall reject any transfer of compliance and risk management tasks.
 - RBC has set up an effective escalation process to ensure that regulatory violations are reported to the compliance department, which in turn reports major violations to the Company's management and the Management Board.
 - RBC has a specialised, separate auditing department, which independently and objectively carries out risk assessments as well as evaluates the suitability and efficiency of internal control procedures and administrative processes.

Based on the above, RBC confirms that no potential conflicts of interest could be identified.

The aforementioned current policy on conflicts of interest is available upon request at the Depositary Bank or at the following link:

https://www.rbcits.com/AboutUs/CorporateGovernance/p_InformationOnConflictsOfInterestPolicy.aspx

3.3 MANAGEMENT COMPANY, CENTRAL ADMINISTRATOR, DOMICILIARY AND PRINCIPAL PAYING AGENT

The Company is managed by MDO Management Company S.A. (the "Management Company"), which is subject to the provisions of Chapter 15 of the 2010 Law.

The Management Company was established on 23 October 2003 for an unlimited period. As at 3 September 2014, the Company's capital amounted to EUR 2,450,000. It is registered under the number B.96744 in the Trade and Companies Register of Luxembourg ("RCS"), where copies of the Articles of Association are available for inspection and can be obtained upon request. The Articles may be consulted and sent out on request. They were published for the first time in the "Mémorial" in Luxembourg on 26 November 2003 and most recently on 14 April 2014. The names and legal documents of all funds managed are available at the domicile of the Management Company and on the web page www.mdo-manco.com.

RBC has been appointed by the Management Company to provide services as administrator, domiciliary agent and as principal paying agent. In consideration of the services rendered, RBC receives a transaction-based remuneration, payable monthly in arrears, as indicated in section 4.6 "fees and expenses".

3.4 REGISTRAR

RBC has been appointed to provide services as the registrar. In consideration of the services rendered, RBC receives a transaction-based remuneration, payable monthly in arrears, as indicated in section 4.6 "fees and expenses".

3.5 INVESTMENT MANAGER

If not indicated differently in the Special Section of the Prospectus for a Sub-Fund, the Management Company and the Company have delegated responsibility for the investment and re-investment of the assets of each of the Sub-funds to Bellevue Asset Management AG.

Bellevue Asset Management AG was founded on 15 April 1994 and is subject to the supervision of the Swiss Financial Market Supervisory Authority FINMA. It is a 100% subsidiary of the Bellevue Group AG., which is listed on the Swiss Stock Exchange SIX as of 2005. The business activities of the Group encompass mainly the Asset Management for institutional and retail clients. As at 31 December 2016, the Assets under Management of the Bellevue Group amounted to CHF 5.2 billion.

The Investment Manager has the discretion to appoint sub-investment advisers (both affiliated and non-affiliated entities).

3.6 AUDITOR OF ANNUAL REPORT

PricewaterhouseCoopers société coopérative, 2, rue Gerhard Marcator, L-2182 Luxembourg, has been appointed auditor of the accounts of the Company.

4. SHARES

4.1 DESCRIPTION OF SHARES

In the corresponding Special Section relating to a specific Sub-fund, the Company will specify the different Share classes offered for such Sub-fund and indicate the different required minimum investments, forms of distribution, fee structures and currencies of such Share classes.

Where a Share class is offered in a currency other than that of the Sub-fund concerned, it must be identified as such. For these additional Share classes the Company may, in relation to the Sub-fund concerned, hedge the Shares in these Share classes against the currency of the Sub-fund. Where such currency hedging is applied, the Company may, in relation to the Sub-fund concerned and exclusively for this Share class, perform foreign exchange forward transactions, currency futures transactions, currency options transactions and currency swaps, in order to preserve the value of the currency of the class against the currency of the Sub-fund. Where such transactions are performed, the effects of this hedging shall be reflected in the Net Asset Value and hence in the performance of the Share class. Similarly, any costs due to such hedging transactions shall be borne by the Share class in which they were incurred. Such hedging transactions may be performed regardless of whether the currency of the Share class rises or falls in relation to the currency of the Sub-fund. Therefore, where such hedging is carried out, it may protect the investor in the corresponding Share class against a fall in the value of the currency of the Sub-fund relative to the currency of the class, though it may also prevent the investor from profiting from an increase in the value of the currency of the Sub-fund.

The Board of Directors of the Company may at any time decide to issue new or additional share classes in a different currency than the base currency.

Shares in the Company have no par value. As described in the Special Section of the Prospectus, the Company will issue only registered Shares for each Sub-fund. Ownership is evidenced by entry in the register of shareholders. Generally, no physical Share certificates will be issued. If requested by a shareholder, share certificates may be delivered to the shareholder by mail on the expense and risk of the shareholder normally within 15 working days (a working day is defined as a day in which the banks in Luxembourg are fully open) after the receipt of the subscription amount. If a shareholder does not request a share certificate, a share-holding confirmation is executed and sent to the shareholder in the same manner as described above. Registered Shares are issued in fractions of Shares, which are rounded up or down to three decimal places. In addition, within each Sub-fund it is possible to issue distributing and accumulating Shares. Distributing Shares entitle the investor to a dividend as determined at the general meeting of shareholders. Accumulating Shares do not entitle the investor to a dividend. When dividend payments are made, the dividend amounts are deducted from the Net Asset Value of the distributing Shares. The Net Asset Value of the accumulating Shares, on the other hand, remains unchanged.

Each Share grants a right to part of the profits and result of the Sub-fund in question. Each Share entitles its owner to a vote, which he may exercise at the general meeting of Shareholders or the separate meetings of the Sub-fund in question either in person or through a proxy. The Shares do not include rights of priority or subscription rights. Nor are they now or will they in the future be associated with any outstanding options or special rights. The Company's shares are transferable without restriction. The Company may, however, in accordance with the Articles of Association, decide to restrict ownership of the Shares to specific persons or organisations ("restricted category of purchasers").

After the launch of the Sub-funds, the Company may issue shares of the Company according to the following criteria and minimal subscription amounts:

- "AB" shares are distributing shares and may be purchased by any investor without any required minimum subscription amount. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.
- "AI" shares are distributing and reserved for institutional investors within the meaning of Article 174 of the Law of 2010, as well as private investors who have signed a consulting or service agreement with a financial intermediary or with an independent asset manager. No minimum investment is required for this class. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.
- "AI2" shares are accumulating and reserved for institutional investors within the meaning of Article 174 of the Law of 2010. A minimum investment is required for the share classes, as defined in the Special Section of the Prospectus. However, the Board of Directors of the Company reserves the right to accept subscriptions in the "AI2" class of less than the minimum investment amount at its discretion, where similar situations arising on the same day must be treated equally. Investments may not go below the minimum investment amount at any time, unless it is as a direct result of a fall in the net asset value. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. No redemption fees are planned.
- "B" shares are accumulating and may be purchased by any investor without any required minimum subscription amount. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.
- "I" shares are accumulating and reserved for institutional investors within the meaning of Art. 174 of the Law of 2010 and private investors who have signed an advisory and services agreement with a financial intermediary or an independent asset manager. No minimum investment is required for this class. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.
- "I2" shares are accumulating and reserved for institutional investors within the meaning of Art. 174 of the Law of 2010. A minimum investment is required for the share classes, as defined in the Special Section of the prospectus. However, the Board of Directors of the Company reserves the right to accept subscriptions in the "I2" class of less than the minimum investment amount at its discretion, where similar situations arising on the same day must be treated equally. Investments may not go below the minimum investment amount at any time, unless it is as a direct result of a fall in the net asset value. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. No redemption fees are planned.

- "T" shares are accumulating and are reserved for employees of the Bank am Bellevue AG and Bellevue Asset Management AG and other pre-defined categories of investors, as defined in due time by the Board of Directors. No subscription fee is levied.

HEDGED SHARE CLASSES

- "HB" shares are accumulating. The currency risk of this share class against another specific currency shall be limited to the extent possible. They are available to all investors without a minimum investment. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.
- "HI" shares are accumulating and reserved for institutional investors within the meaning of Art. 174 of the Law of 2010 and private investors who have signed an advisory and services agreement with a financial intermediary or an independent asset manager. No minimum investment is required for this class. The currency risk of this share class against another specific currency shall be limited to the extent possible. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.
- "HI2" shares are accumulating and reserved for institutional investors within the meaning of Article 174 of the Law of 2010. A minimum investment is required for the share classes, as defined in the Special Section of the prospectus. However, the Board of Directors of the Company reserves the right to accept subscriptions in the "HI2" class of less than the minimum investment amount at its discretion, where similar situations arising on the same day must be treated equally. Investments may not go below the minimum investment amount at any time, unless it is as a direct result of a fall in the net asset value. The currency risk of this share class against another specific currency shall be limited to the extent possible. A subscription fee of max. 5% of the respective net asset value per share may be levied in favour of the distribution partner. Redemption fees are not foreseen.

All shares may be issued in USD, EUR, GBP and CHF.

4.2 GENERAL NOTES ON THE SUBSCRIPTION, REDEMPTION AND SWITCHING OF SHARES

SUBSCRIPTION

The Shares are offered for sale on each Dealing Day following the initial issue.

Subscription requests may either be sent to any distribution partner, which shall forward them to RBC, or may directly be sent to the Company for the attention of RBC. The subscriber should instruct his bank to transfer the amount due to the applicable foreign exchange account of RBC a, giving precise details of the identity of the subscriber(s), the Sub-fund(s) to which the subscription relates, and, within each Sub-fund, which share category is subscribed for in the Sub-fund.

The following cut-off times apply for subscriptions to shares if not otherwise provided for in the Special Section of a sub-fund. Subscriptions received by RBC prior to 15.00 local Luxembourg time (Cut-Off time) at any Dealing Day (as defined under section "Calculation of the Net Asset Value") will be treated at the at the issue price determined at the following valuation day. Subscriptions received by RBC after this time are covered by the issue price of the valuation day after the following valuation day. To ensure punctual transmission to RBC, applications placed with distribution partners in Luxembourg or abroad may be subject to earlier cut-off times for the delivery of subscription applications. These times can be obtained from the distribution partners concerned.

Hence, the shares are therefore acquired at an unknown net asset value (forward pricing).

The shares are issued at an issue price based on the net asset value per share on the relevant valuation day, rounded as defined for each Sub-fund in the Special Section of the Prospectus, plus any applicable subscription fee levied by a distribution partner or the Company. Further details of the issue price may be obtained from the registered office of the Company.

If not explicitly requested by an investor, no physical share certificates are issued, but kept by the paying agent or a bank designated bank by the latter for and on behalf of the investor. The delivery of share certificates is at the expense and risk of the investor. The Company reserves its right to deny subscription requests or to only partially accept them or to ask for additional documents and/or information. In case of full or partial denial of a subscription request, the whole subscription amount or the respective balance is transferred to the subscriber.

The total subscription amount must be booked in Luxembourg in the currency and in the share class of the respective Sub-fund within three (3) Luxembourg banking days or according to national regulations after a certain time period after the valuation day.

Investors can subscribe for Shares directly from the Company. Investors may also purchase Shares in a Sub-fund by using the nominee services offered by the relevant Distributor or its correspondent bank. The distributor or its correspondent bank is subject to supervision by an authority with its registered office in the EU, a Member State of the EEA or a third country that is governed by rules that are comparable with the Luxembourg law of 29 July 2008. The distributor or correspondent bank then subscribes to and holds the shares as a nominee in its own name, but for the account of the investors. The distributor or the correspondent bank then confirms the subscription to the shares in a confirmation letter to the investors. Distributors that offer nominee services that have their registered office in an EU country, an European Economic Area country or in other countries that have equivalent regulations within the meaning of the Grand-Ducal Regulation of July 29, 2008 or settle their transactions via a correspondent bank with its registered office in the EU, a European Economic Area country or in other countries that have equivalent regulations within the meaning of the Grand-Ducal Regulation of July 29, 2008.

Investors who make use of the Nominee-Service may give the nominee instructions with regard to the execution of its voting rights and may at any time ask the distribution partner or the custodian bank in writing for direct ownership.

The Company reserves its right to – fully or partially – deny any subscription. In this case, already made payments are reimbursed to the investor without any interest.

In addition, the Company or the Management Company may refuse to accept new applications from new investors for a specific period if this is in the interests of the Company and/or Shareholders, including situations where the Company or a Sub-fund have reached a size such that they can no longer make suitable investments.

Subscriptions and redemptions shall be made for investment purposes only. Neither the Management Company, nor the Company or RBC allow “market timing” or similar excessive trading practices. Such practices may damage the performance of the Company and its Sub-funds and may have a negative impact on the management of the assets. In order to minimize such negative consequences, the Company, the Management Company and RBC preserve the right to deny subscription and/or redemption orders from investors who may practice such trading procedures from their point of view.

The Company and the Management Company may also compulsorily redeem the Shares of a Shareholder engaging in or having engaged in such practices. The Company shall not be liable for any gain or loss resulting from such rejected applications for subscription or conversion or compulsory redemptions.

REDEMPTION

The following cut-off times apply for redemptions of shares if not otherwise provided for in the Special Section of a sub-fund. The application for redemption of shares must be made by the investor in writing, directly or via a distribution partner to the Company (for the attention of RBC) no later than 15.00 local Luxembourg time (the Cut-Off time) at the day before the valuation day, at which the shares shall be redeemed.

Hence, the shares are redeemed for an unknown net asset value (forward pricing).

Share certificates which have been sent to an investor must in case of distributing shares include all interest coupons not yet paid out. A correctly submitted application for redemption is irrevocable, except in the case of and during the period of a suspension or postponement of redemption.

Applications for redemptions received after the time specified above are processed one valuation day later unless the Company, in receipt of applications for redemption corresponding to more than 10% of the net asset value of the relevant Sub-fund, decides to postpone all redemptions.

The redemption price per Share corresponds with the Net Asset Value of the Shares attributable to the relevant class thereof calculated at the valuation day, deducting therefrom such amount as may be necessary to round the resulting total as outlined in the Special Section of the Prospectus for each Sub-fund. A possible redemption fee as described in the Special Section of the Prospectuses may be waived. In order to calculate the redemption price at the valuation day, the Company must receive the redemption application, any share certificates if sent to the investor, and in case of distributing shares, the respective coupons.

If the calculation of the Net Asset Value is suspended or redemption is postponed, Shares offered for redemption will be redeemed on the next Dealing Day after the suspension of valuation or the postponement of redemption has ended at the Net Asset Value applying on that day, unless the redemption request has previously been revoked in writing.

Payments are normally made in the currency of the relevant Sub-fund or Share class on or before five (5) bank business days in Luxembourg after the later of the Dealing Day concerned or the date on which the Share certificates are returned to the Company.

In special cases, the Company's Board of Directors may decide to pay the redemption proceeds to the Shareholders on request in the form of a full or partial payment in kind. It must be ensured that all Shareholders are treated equally and the auditor of the Company's annual report must make an independent valuation of the payment in kind, the cost of which may be borne by the Shareholder requesting such redemption in kind.

If, upon execution of a redemption application for part of the Shares of a Sub-fund, the total number of Shares held in one of these Sub-funds falls below the minimum investment set out in the Supplement of the Sub-fund in question, or below the minimum number otherwise determined by the Board of Directors, the Company is entitled to redeem all remaining Shares in that Sub-fund owned by the particular investor.

The Company is not obliged to redeem more than 10% of all issued Shares in a Sub-fund on one Dealing Day or within a period of seven (7) consecutive Dealing Days. For the purposes of this provision, the switching of Shares of a Sub-fund is deemed to constitute redemption of the Shares. If, on any Dealing Day or over a period of seven (7) consecutive Dealing Days, the number of Shares for which redemption is requested is greater than indicated above, the Company may postpone the redemptions or switches until the seventh Dealing Day thereafter. Such applications for redemption/switching will take precedence over applications received subsequently. For this purpose, the switching of Shares of a Sub-fund is deemed to constitute redemption.

All redeemed Shares are cancelled.

The redemption price may be obtained from the registered office of the Company or from one of the Distributors and is published in the relevant daily newspapers.

SWITCHING

Every investor may request to switch some or all of its shares in shares of another Sub-fund on a valuation day which can be used for both Sub-funds, as well as within one Sub-fund from one share class into another share class, in accordance with the Switching rules as defined hereinafter and in accordance with the principles as outlined by the Board of Directors for each Sub-fund.

A switch into another share class may only be executed if the investor complies with requirements for that specific share class. The Board of Directors may define the conditions for switches for each Sub-fund with regard to the frequency of switches, the Sub-funds qualifying for switches and the possible application of a redemption fee (as defined in the Special Section of the Prospectus for each Sub-fund).

Shares may be converted on the valuation day at the issue price applicable on this day, provided that the conversion order is received by the company (for the attention of RBC) no later than the earlier cut-off time between the two sub-funds concerned on the day before the valuation day. The provisions regarding the cut-off-time and forward-pricing also apply to converting (see sub-paragraphs "Issue" and "Redemption" of this section).

Orders are sent either directly to the Company for the attention of RBC or to the distributors. The order must contain the following information: the number of distribution or capitalisation shares of the sub-fund to be converted and the name of the new sub-fund required as well as the ratio at which the distribution or capitalisation shares will be distributed in each sub-fund if more than one new sub-fund is affected.

The number of Shares to be issued in any New Sub-fund will be calculated in accordance with the following formula:

$$A = \frac{[(B \times C) - E] \times F}{D}$$

where:

A = the number of Shares to be issued in the New Sub-fund;

B = the number of Shares of the Original Sub-fund to be converted;

- C = the redemption price per Share of the Original Sub-fund on the relevant Dealing Day, less any selling costs;
- D = issue price per share of the new Sub-fund, plus reinvestment costs;
- E = switching fee, if any (max. 1% of the net asset value) – whereby comparable switching requests on the same day are charged the same switching fee;
- F = exchange rate; if the old and the new Sub-fund have the same currency, the exchange rate is 1.

It is to be noted that the switch of shares represented by certificates may only be executed the receipt of such certificates (incl. possible interest coupons).

A possible switching fee is in favour of the distribution partner. If not defined differently in the Special Section of the Prospectus, a switching fee may amount to max. 1% of the net asset value of any Sub-fund.

4.3 CALCULATING THE NET ASSET VALUE

The net asset values of the different Sub-funds are calculated as follows:

ASSETS OF THE COMPANY

The assets of the Company include the following:

- a) all available cash on hand or on account plus accrued interest;
- b) all bills of exchange and other credit balances on demand (including the proceeds from sales of securities that have not yet been credited);
- c) all securities (shares, fixed and variable interest securities, bonds, options or subscription rights, warrants and other investments and securities held by the Company);
- d) all dividends and distributions due to the Company in cash or in kind, to the extent known to the Company; the Company must however adjust the valuation as a result of fluctuations of the market value of securities due to trading practices such as the trading of ex-dividends or ex-subscription rights;
- e) all accrued interest in interest-bearing securities which the Company holds, provided such interest is not included in the principal claim;
- f) all financial rights resulting from the use of derivative instruments;
- g) the provisional expenditure of the Company, unless this has been written down, provided such provisional expenditure may be written down directly from the Company's capital; and
- h) all other assets of any kind and composition, including prepaid expenditure.

The value of such investments is determined as follows:

- a) The value of freely available cash balances or deposits, bills of exchange and sight balances, prepaid expenditure, cash dividends and interest as confirmed or accrued, but not received, as shown above, will be entered for the full amount, unless for any reason the payment is less likely or only partly collectible, in which case its value shall be determined after making a deduction, with the aim of ascertaining the effective value to the best knowledge of the Company.
- b) Securities forming part of the assets which are officially listed or are traded at another regulated market will be valued at the last available price at the principal market at which these securities are traded. The services of an agent approved by the Board of Directors may be used for this purpose. Securities, the price of which is not based on market values, and all other permissible investment securities (including securities not officially listed at a stock exchange or traded at a regulated market), will be inserted at their probable realisation values, which will be determined in good faith by or under the direction of the Company management.
- c) All assets or liabilities that are not denominated in the currencies of the Sub-fund in question will be converted into the currency relevant to that Sub-fund at the exchange rate notified at the valuation time by a bank or another responsible financial institution.
- d) Shares that are issued by UCI of the open category are to be valued at their last available asset value at the rate at the place at which they were listed.

- e) The realisable value of forward, future or option agreements that were not negotiated at a stock exchange or another organised market will be valued in accordance with the guidelines laid down by the Board of Directors and in an invariable fashion. The realisable value of forward or option agreements which are negotiated at a stock exchange or other organised markets will be valued based on the last available settlement prices for these agreements at stock exchanges and organised markets at which forward or option agreements of this kind are negotiated; this applies with the proviso that in the case of forward or option agreements that could not be realised on a valuation date, the value regarded by the Board of Directors as appropriate and reasonable is the basis for determining the realisable value of this agreement.
- f) The valuation of liquid funds and money market instruments may be carried out at the relevant nominal value plus accrued interest while taking account of the scheduled depreciation of historical costs. The last mentioned valuation method may lead to the value temporarily deviating from the rate that the Company would receive in selling the investment. The Company will check this valuation method in each instance and regularly recommend amendments to ensure that the valuation of these asset values will be conducted at their appropriate value, which will be determined in good faith in line with the procedures prescribed by the Board of Directors. Should the Company feel that a departure from the scheduled depreciation in costs per share would lead to substantial dilution or other results inappropriate to the shareholders it must, if appropriate, carry out corrections that it regards as appropriate to rule out or limit dilution or inappropriate results, as far as this is possible within the appropriate limits.
- g) The swap transactions are regularly valued based on the valuations received from the swap counterparty. The values may be the bid price, offering price or average price as determined in procedures laid down in good faith by the Board of Directors. If, in the view of the Board of Directors, these values fail to reflect the appropriate market value of the swap transactions in question, the value of the swap transactions will be determined by the Board of Directors in good faith or in accordance with another method that the Board of Directors feels to be appropriate.
- h) If, because of particular circumstances such as for example a hidden credit risk, valuation is impossible to carry out or incorrect in accordance with the above rules, the company shall be entitled to apply other generally acknowledged valuation principles verifiable by auditors, to achieve an appropriate valuation of the assets.

LIABILITIES OF THE COMPANY

The liabilities of the Company shall include the following

- a) all borrowings, bills of exchange and other amounts due, including security deposits such as margin accounts etc. in connection with the use of derivative instruments; and
- b) all due or accrued administrative expenditure including foundation and registration costs at registration offices and also charges for legal advice, audit fees, all fees of investment managers and investment advisers, the custodian, distributors and all other representatives and agents of the company, the costs of obligatory publications and the prospectus, the annual accounts and other documents made available to the shareholders. If there is a discrepancy between the rates agreed between the company and the service providers that it has commissioned such as investment managers, investment advisers, marketing advisers and custodian bank for such services with regard to individual Sub-funds, the relevant different fees are to be charged exclusively to the Sub-funds in question; and
- c) all known liabilities due and not yet due, including dividends declared but not yet paid; and
- d) an appropriate amount set aside for tax, calculated for the day of the valuation as well as other provisions or reserves approved by the Board of Directors; and
- e) all other liabilities of the Company of any kind to third parties.

Any liability of any kind to third parties is restricted to the Sub-fund or Sub-funds in question.

For the purposes of evaluating its liabilities the Company may include all administrative and other expenditure that is regular or periodic by assessing it for the whole year or any other period and allocating the resultant amount proportionately to the relevant period of time that has accrued. This valuation method may only relate to administrative and other expenditure that concerns all Sub-funds to the same extent.

DETERMINING THE ASSETS

The Board of Directors of the Company will determine the assets of each Sub-fund as follows:

- a) The proceeds from allocating and issuing shares for each Sub-fund shall be assigned in the Company books to those assets for which this Sub-fund has been set up and the relevant assets and liabilities, income and expenditure shall be assigned to these assets in accordance with the guidelines of this article.
- b) If any asset has been derived from another asset, derived assets of this kind shall be assigned in the Company books to the same Sub-fund as the assets from which they originate and with every new valuation of an asset the growth or loss in value will be assigned to the Sub-fund in question.
- c) If the Company has accepted a liability that is connected to any asset or a particular Sub-fund or to any activity connected to an asset of a Sub-fund, this liability will be assigned to the Sub-fund in question.
- d) if an asset or a liability in the Company cannot be regarded as a dimension assignable to a particular Sub-fund and does not relate to all Sub-funds to an equal extent either, the Board of Directors may allocate such assets or liabilities in good faith;
- e) from the day on which a dividend is declared for a Sub-fund, the net asset value of this Sub-fund is reduced by the amount of the dividend, always however subject to the rules for the sale and redemption price for shares in the Sub-fund as set out in these articles.

VALUATION

For the purposes of valuation within the scope of this article the following shall apply:

- a) Shares that are repurchased in accordance with Article 23 of the Articles shall be treated as existing and posted until immediately after the point in time laid down by the Board of Directors or its authorised representatives at which such a valuation is carried out and from this point in time onwards until the price is paid for this they will be treated as a liability of the Company;
- b) all investments, cash and other assets forming part of a Fund's assets which are not in the currency of the Sub-fund in question will be converted with reference to their market value at the exchange rate applicable on the day on which the net asset value is calculated; and
- c) on that valuation date all purchases and sales of securities concluded by the company on this very valuation date must as far as possible be included in the valuation.

4.4 VALUATION DATE

The valuation date for each Sub-fund is that bank working day in Luxembourg which is not at the same time a normal holiday for the banks or other markets that constitute a valuation basis for a substantial portion of the net asset value of the relevant Sub-fund, as determined by the company.

4.5 SUSPENDING CALCULATION OF THE NET ASSET VALUE, THE ISSUE, THE REDEMPTION AND THE EXCHANGE OF SHARES

The Company may temporarily suspend calculation of the net asset value of each Sub-fund and the issue, redemption and exchange of shares in a Sub-fund:

- a) if one or more stock exchanges or other markets which constitute the basis of valuation for a substantial portion of the net asset value are closed (apart from normal holidays) or trading is suspended;
- b) if the Company feels because of special circumstances that it is impossible to sell or value assets;
- c) if the communication technology normally employed to determine the price of a security forming part of this Sub-fund has broken down or can only be used to a limited extent;
- d) if it is impossible to transfer cash to purchase or sell capital investments in the Company; or
- e) if a decision is made to liquidate the Company: on or after the day on which the first convening of a General Meeting of investors for this purpose is published.

The Company's Memorandum of Association stipulates that the Company should suspend the issue and exchange of shares without delay as soon as an event resulting in liquidation occurs or the Luxembourg supervisory authority orders this. Investors who have offered their shares for redemption or exchange will be notified of a suspension in writing within seven (7) days and without delay as soon as it comes to an end.

4.6 FEES AND COSTS

The Company pays a management fee, which is laid down for the Sub-fund in question in the Special Section of the prospectus. This management fee includes compensation for the investment managers / investment advisors.

The Management Company has implemented a remuneration policy pursuant to Directive 2014/91/EU of the European Parliament and the Council of 23 July 2014 amending Directive 2009/65/EC on the coordination of laws, regulations and administrative provisions relating to undertakings for collective investment in transferable securities.

The remuneration policy sets out principles for the remuneration of the senior management, all employees who have a significant influence on the risk profile of the UCITS, and all employees who perform independent control functions.

The Management Company applies the following principles in a way and to the extent that is appropriate to its size, its internal organisation and the nature, scope and complexity of its activities:

- i. The remuneration policy is consistent with and promotes sound and effective risk management and does not encourage risk-taking which is inconsistent with the risk profiles, contractual terms or articles of association of the UCITS they manage;
- ii. If and to the extent applicable, the performance assessment is carried out in a multiannual framework which is appropriate to the holding period recommended to the investors of the UCITS managed by the Management Company to ensure that the assessment is based on the longer-term performance of the UCITS and its investment risks and the actual payment of performance-related remuneration components is distributed over the same period;
- iii. The remuneration policy is consistent with the business strategy, objectives, values and interests of the Management Company and the UCITS it manages and the investors of such UCITS, and includes measures to avoid conflicts of interest.
- iv. There is an appropriate relationship between the fixed and variable components of the total remuneration, with the proportion of the fixed component of the total remuneration high enough to offer complete flexibility in terms of variable remuneration components, including the option of paying no variable remuneration component at all.

The remuneration policy is established and reviewed annually by a remuneration committee.

The details of current remuneration policy of the Management Company include, among others, a description of the way in which the remuneration and benefits are calculated, information on those responsible for the granting of remuneration and benefits, as well as the composition of the Remuneration Committee. These details are available at <http://www.mdo-manco.com/remuneration-policy> or upon request in paper form at no charge.

The fees for the custodian bank, the fund management company, central administration agent and the registrar and the Management Company together average up to 0.40% p.a. of the net assets of the Company, depending on the Sub-fund. The aforementioned figure may however be higher or lower according to the Company's net assets.

The Company will also pay costs arising from the Company's business operation. These include the following costs:

Costs of the operational running and the supervision of the company's business activities (including risk management and investment compliance), of tax, costs of legal auditing and accountancy services, business reports and prospectuses, publication costs for convening the General Meeting, share certificates and the payment of dividends, registration fees and other costs due to or in connection with reporting to supervisory bodies in the various jurisdictions, sales support, paying agents and representatives, fees and disbursements of the company's Board of Directors, insurance premiums, stock exchange licensing and brokers' fees, purchasing and selling securities, government levies, licensing fees, payment of disbursements to the custodian bank and all other parties contracting with the Company along with the costs of publishing the net asset value of each share and the share prices.

Furthermore, the Company may pay fees for additional services provided to ensure compliance with new supervisory requirements.

If such expenditure and costs relate to all Sub-funds to an equal extent then each Sub-fund will be charged a proportion of the costs depending on its share in terms of volume of the total assets of the Company. Where expenditure and costs only relate to one or individual Sub-funds, the Sub-fund or Sub-funds will be charged in full or proportionally.

In the sub-funds that can invest in other existing UCIs or UCITS as part of their investment policy, charges can be incurred both at the level of the investment fund ("target fund") in question and at company level. Should a sub-fund acquire units in UCIs or UCITS which are indirectly or directly managed by the Management Company itself or by a company with which it is associated by a joint management or control or by a direct or indirect participation of more than 10% of the capital or the votes ("associated target fund"), no management fee will be charged at the level of the target fund. When investments are made in shares of associated target funds no offering or redemption commission may be charged for subscribing to or redeeming these shares.

For Sub-funds with authorised management expenditure there may be provision for an additional performance-related fee payable to the investment manager / investment adviser. This is calculated from the performance per share and is measured based on a percentage of that portion of realised profit that lies above a predefined benchmark for this Sub-fund. Account will be taken of a negative performance in the course of a business year when calculating this performance fee by transferring this performance fee to the following business year or years and offsetting it against the positive performance of such business years.

In case that additional costs in connection with the registration of the Company arise in additional distribution countries (e.g. costs for a local representative, a local paying agent, a local correspondence bank, additional transaction costs, etc.), the Company may pay such additional costs itself or may charge them to the respective investors.

All fees, costs and expenditure that is to be borne by the Company will first of all be offset against income and then against capital. The costs and expenditure for organising and registering the Company as a UCITS in Luxembourg which does not exceed EUR 250,000 were borne by the Company and written off in equal amounts over a period of five (5) years from the date of its origination. The costs of opening, activating and registering an additional Sub-fund will be charged to this Sub-fund and written off in equal amounts over a period of five (5) years from the date of activation of this Sub-fund.

5. INVESTMENTS

5.1 INVESTMENTS OF THE COMPANY

INVESTMENT OBJECTIVES AND INVESTMENT POLICY

The investment objectives of the Board of Directors regarding each individual Sub-fund are described in the Special Section under "Investment objectives and policy".

In so far in this Prospectus, especially in its Special Section, reference is made to "recognized countries", "recognized country" means a member state of the Organisation for Economic Co-Operation and Development ("OECD") and all other countries in Europe and all other countries in Europe, North and South America, Africa, Asia and the Pacific basin (hereinafter referred to as "**recognized country**").

As well as this the Sub-funds may employ investment techniques and financial instruments in the course of pursuing their investment objectives, as described below in the chapter "**Special investment techniques and financial instruments**", under the guidelines and limits established in accordance with Luxembourg law.

Although the Company endeavours to the best of its knowledge to achieve the investment objectives of the individual Sub-funds, no guarantee can be given as to how far the investment objectives are achieved. Consequently the net asset values of the shares may become larger or smaller and different levels of positive and even negative earnings may result.

The performance of the respective Sub-funds is shown in the KIID.

CO-MANAGEMENT/POOLING

In order to reduce ongoing management expenditure and at the same time to facilitate a broader diversification of investments, the Company may decide to arrange for a portion of the assets or the entire assets of a Sub-fund to be managed jointly with the assets belonging to other Luxembourg UCIs, which are managed by the same management company and launched by the same promoter, or arrange for various or all Sub-funds to be managed jointly with one

another. In the following paragraphs the words "jointly managed units" refer generally to those Sub-funds and all units with which or between which there is a given agreement or joint management, and the words "jointly managed assets" refer to the entire assets of these jointly managed units that are managed under this agreement.

Under this agreement on joint management, investment and realisation decisions can be made for the relevant jointly managed units on a consolidated basis. Every jointly managed unit holds a portion of the jointly managed assets, which corresponds to the proportion of its net asset value to the total value of the jointly managed assets. This proportional ownership is applicable to every category of investments that is held or acquired under joint management. The investment and/or realisation decisions do not affect this proportion of the inventory and additional investments are assigned to the jointly managed units in the same proportion and sold assets are withdrawn from the jointly managed assets held by each jointly managed unit pro rata.

When subscribing to new shares in one of the jointly managed units, the subscription proceeds are assigned to the jointly managed units in the new proportion resulting from the increase in the net asset value of the jointly managed units to which the subscriptions have accrued and all categories of investment will be changed by transferring assets from one jointly managed unit to the other and so adapted to the change in ratios. Similarly, when shares in one of the jointly managed units are redeemed the necessary cash is withdrawn from the jointly managed units in line with the changed proportions resulting from the reduction in the net asset value of the jointly managed units to which the redemption of shares has been charged, and in such cases all categories of investment will be adjusted to the change in circumstances. Shareholders should therefore be aware that the agreement on joint management may result in the composition of the portfolio of the Sub-fund in question being influenced by events that are due to other jointly managed units, such as subscriptions and redemptions for example. Consequently, provided there are no other changes, subscriptions made to shares in the unit with which the Sub-fund is jointly managed will lead to an increase in the cash available to this Sub-fund. On the other hand redemptions of loans relating to a unit with which a Sub-fund is jointly managed leads to a reduction in cash for this Sub-fund. Subscriptions and redemptions can however be held in the specific account opened for every jointly managed unit which is held outside the agreement via the joint management and through which subscriptions and redemptions must pass. The possibility of allocating substantial payments and redemptions to the specific accounts together with the possibility for participation of a Sub-fund in the agreement to be terminated at any time via the joint management enable it to avoid changes in the portfolio of a Sub-fund caused by other jointly managed units, where this adjustment would probably damage the interests of the Sub-fund and the shareholders.

If a change in the composition of the assets in a Sub-fund resulting from redemptions or payments of charges and expenses which relate to another jointly managed unit (i.e. are not assignable to the Sub-fund) would lead to an infringement of the investment restrictions applicable to this Sub-fund, the relevant assets will be excluded from the agreement on joint management before the changes are made so that they are not affected by the resultant adjustments.

Jointly managed assets of a Sub-fund may only be managed jointly with assets that are to be invested in accordance with investment objectives that are compatible with those that are applicable to the jointly managed assets of the Sub-fund in question, in order to ensure that investment decisions are fully compatible with the Sub-fund's investment policy. Jointly managed assets of a Sub-fund may only be managed jointly with assets for which the custodian bank also functions as custodian in order to ensure that the custodian bank can fully comply with its functions and tasks as set out in the Law of 2010. The custodian bank must always keep the assets of the Company separate from the assets of other jointly managed units and must therefore always be in a position to identify the Company's assets. As jointly managed units may pursue an investment policy that does not agree 100% with the investment policy of one of the Sub-funds, it is possible that as a consequence the policy jointly applied is more restrictive than that of the Sub-fund.

The Company may at any time and without notice decide to end the agreement on joint management.

Shareholders can at any time contact the Company's head office to obtain information regarding the percentage of the asset that is jointly managed and on the units with which such joint management exists at the time of their enquiry. Annual and semi-annual reports must state the composition and percentages of the jointly managed assets.

5.2 INVESTOR PROFILE

The investor profile of the individual Sub-funds is described in the Special Section of the Prospectus.

5.3 INVESTMENT RESTRICTIONS

INVESTMENTS IN SECURITIES, MONEY MARKET INSTRUMENTS, DEPOSITS AND DERIVATIVES

These investments consist of:

- a) Securities and money market instruments:
 - that are listed or traded on a regulated market (as defined in Article 41 of the Law of 2010);
 - that are traded on another regulated market of a member state of the European Union ("EU") which is recognized, open to the public and which operates in a proper manner;
 - which is officially listed on a stock exchange of a third country¹ or traded on another regulated market of a third country which is recognized, open to the public and which operates in a proper manner;
 - Securities and money market instruments from new issues, where the issue conditions include the obligation for an application to have been made for admission to official listing at a stock exchange or at another regulated market which is recognized, open to the public and which operates in a proper manner and that the listing takes place no later than one year after issue.
- b) Demand deposits or deposits subject to call with a term of at least 12 months at authorised financial institutions, where the financial institution in question has its head office in a member state of the EU or in a member state of the OECD, or, if the head office of the financial institution is in a third country, it is subject to supervisory provisions, which the CSSF feels are equivalent to those of community law (an "authorised financial institution").
- c) Derivatives including equivalent instruments calculated in cash, which are traded on a regulated market indicated under (a) first, second and third dash, and/or derivatives traded on the open market ("over the counter" or "OTC"), where:
 - the underlying instruments are instruments in accordance with this Subsection 1 or financial indices, interest rates, exchange rates or currencies in which the Sub-fund may invest in accordance with its investment objectives;
 - the counterparties in transactions with OTC derivatives are institutions subject to supervision in the categories that have been licensed by the Commission de Surveillance du Secteur Financier ("CSSF"); and
 - the OTC derivatives are subject to a reliable and verifiable valuation on a daily basis and can at any time at the Company's initiative be sold, liquidated or closed by an offsetting transaction at the appropriate fair value.
- d) Shares of UCITS and/or other UCIs within the meaning of Directive 2009/65 EC (hereinafter "Directive 2009/65 EC") within the meaning of Article 1 paragraph 2. A and B of Directive 2009/65 EC with a registered office in the European Union Member State or in another country, provided:
 - these other UCIs are licensed in accordance with the legal provisions which subject them to official supervision, which the CSSF feels is equivalent to those under EU community law and there is an adequate guarantee of co-operation between the authorities;
 - the level of protection for shareholders of other UCIs is equivalent to the level of protection of shareholders of an UCITS and in particular the provisions for the separate custody of fund assets, borrowings, loan approvals and short selling of securities and money market instruments is equivalent to the requirements of Directive 85/611/EEC;
 - the business activity of the other UCIs is the subject of semi-annual and annual reports which allow a judgement to be formed on the assets and liabilities, income and transactions in the period under review;
 - the UCITS or this other UCI, the shares of which are to be purchased, may not, according to its foundation documents, invest more than 10% of its net asset value in shares of other UCITS or other UCIs.
- e) Money market instruments that are not traded on a regulated market and which fall under the definition of Article 1 of the Law of 2010, where the issue or the issuer of these instruments is itself subject to regulations regarding deposit and investor protection and provided they are:

¹ In the standard usage of Directive 2009/65/EC a third country is a country that is not a member state of the EU.

- floated or guaranteed by a central government, regional or local body or the central bank of a member state of the EU, the European Central Bank, the EU or the European Investment Bank, a third country or, in the case of a federal state, a member state of the federation or by a public international establishment to which at least one member state of the EU belongs; or
- floated by a company, the securities of which are traded in the regulated markets referred to under 1. (a); or
- floated or guaranteed by an institute that is subject to supervision in accordance with the criteria laid down under EU community law, or an institute that is subject to supervisory provisions that the CSSF feels are at least as strict as those of EU community law and adheres to them; or
- they are issued by other issuers belonging to a category licensed by the CSSF where regulations for investor protection apply to investments in these instruments which are equivalent to those of the first, second or third dash and where the issuer is either a company with equity capital of at least ten (10) million EUR which draws up and publishes its annual financial statements in accordance with the provisions of Directive 4. 78/660/EEC or a legal entity which is responsible for the financing of a group encompassing one or more stock exchange listed companies, or a legal entity dedicated to the financing of securitisation vehicles which benefit from a banking liquidity line.

f) Nevertheless:

- the Company may not invest more than 10% of the net asset value of its Sub-funds in securities and money market instruments other than those referred to under (a) to (e);
- the Company may not purchase either precious metals or certificates through these.

g) The Company may also retain liquid funds.

CROSS-INVESTMENTS BETWEEN SUB-FUNDS OF THE COMPANY

A Sub-fund (the “cross-investing sub-fund”) may invest in one or several other sub-funds of the Company.

With regard to the purchase of shares in another Sub-fund (the “target sub-fund”) of the Company, the following conditions are applicable:

- a) The target sub-fund may not invest into the cross-investing sub-fund;
- b) the target sub-fund may invest no more than 10% of its total net assets in UCITS (including other sub-funds) or other UCI as defined in pt. 5.3.d of section 5;
- c) the voting rights linked to the shares of the target sub-fund will be suspended during the period of the cross investment by the cross-investing sub-fund.
- d) the value of the shares in the target sub-fund, which are held by the cross-investing sub-fund, will not be considered for calculating the required minimal capital of 1,250,000.
- e) the accumulation of subscription, redemption and/or switching commissions are not allowed.

INVESTMENT RESTRICTIONS

- a) The Company shall not invest more than 10% of the net asset value of any Sub-fund in securities or money market instruments of one and the same issuer.

The company shall not invest more than 20% of the net asset value of any Sub-fund in deposits at one and the same institution. The default risks for transactions of the company with OTC derivatives may not exceed the following rates.

- 10% of the net asset value of each Sub-fund if the counterparty is an authorised financial institution;
- and otherwise 5% of the net asset value of each Sub-fund.

For each sub-fund, the Company shall ensure that the overall risk associated with derivatives does not exceed the total net asset value of the relevant sub-fund in each case. In calculating this risk, the market value of the underlying assets, the risk of counterparty default, future market fluctuations and the time required to liquidate the positions will be taken into account. After the assessment of the overall risk profile associated with the investment policy (including, but not limited to the possible use of financial derivatives and their characteristics) of each sub-fund, the Management Company shall calculate the overall risk of the sub-fund using either the value-at-risk (VaR) model or the commitment approach in accordance with the applicable European and Luxembourg laws and/or regulatory provisions (in particular CSSF Circular 11/512).

The aggregate exposure of the underlying instruments must not exceed the investment limits in Subsections (a) to (f). The underlying instruments of index-based derivatives need not take account of these investment limits. If a derivative is embedded in a security or money market instrument it must also be taken into account as far as the provisions of this point are concerned.

- b) The total value of the securities and money market instruments of the issuers in which a Sub-fund invests more than 5% of its net asset value must not exceed 40% of its net asset value. This limit does not apply to deposits and transactions with OTC derivatives that are concluded with financial institutions that are not subject to official supervision.
- c) Irrespective of individual upper limits referred to under (a), a Sub-fund may not invest more than 20% of its net asset value in one and the same establishment in a combination arising from:
 - securities or money market instruments floated by this establishment and/or
 - investments in this establishment and/or
 - OTC derivatives purchased from this establishment.
- d) The upper limit under (a), first sentence is raised to 35% if the securities or money market instruments are issued or guaranteed by a member state of the EU or its central, regional and local authorities, by a third country or by public international establishments to which at least one member state belongs.
- e) The upper limit under (a), first sentence is raised to 25% for certain debentures if these are issued by a financial institution with a registered office in a Member State of the EU, which is subject to special official supervision based on statutory provisions to protect the holders of these debentures. In particular the earnings from the issue of these debentures must, according to statutory provisions, be invested in assets which adequately cover the resultant liabilities for the whole term of the debentures and are primarily intended for the repayment of capital and interest that will become due if the issuer defaults.

If the Sub-fund invests more than 5% of its net asset value in debentures as described in the above paragraph, which are issued by one and the same issuer, the total value of these investments must not exceed 80% of the net asset value of this Sub-fund.

- f) The securities and money market instruments referred to under (d) and (e) will not be taken into account in applying the investment limit of 40% provided for under (b).

The limits referred to under (a) to (e) must not be accumulated; consequently, investments in securities or money market instruments of one and the same issuer or deposits with this issuer or in derivatives of the same concluded in accordance with (a) to (e) must never exceed 35% of the net asset value of a Sub-fund.

Companies that belong to the same corporate group in terms of drafting a consolidated annual financial statement pursuant to Directive 83/349/EEC or in accordance with recognized international accounting rules shall be regarded as a single issuer when assessing the investment limits provided for above.

The investments of a Sub-fund in securities and money market instruments of one and the same corporate group must not together exceed 20% of its net annual value.

- g) Notwithstanding points (a) to (f) the Company is authorised, in agreement with the principle of risk diversification, to invest up to 100% of the net asset value of a Sub-fund in securities and money market instruments of different issues, issued or guaranteed by a member state of the EU or its central, regional and local authorities or a member state of the OECD or by international public organisations to which one or more member states of the EU belong, while subject to the proviso that the Sub-fund must hold securities and money market instruments of

at least six different issues whereby the securities and money market instruments of an issue must not exceed 30% of the net asset value of the Sub-fund.

- h) Notwithstanding the investment limits laid down in subsection (j) the upper limit for investments in shares and/or debentures with one and the same issuer referred to in paragraph (a) may not be increased to more than 20% if the investment strategy of a Sub-fund is to track a certain share or bond index recognized by the CSSF; it is a requirement of this that
- the composition of the index is sufficiently diversified;
 - the index presents an adequate reference basis of the market to which it refers;
 - the index is published in an appropriate fashion.

The limit specified in the above paragraph is 35%, where this is justified on the basis of unusual market conditions, particularly in regulated markets which are heavily dominated by certain securities or money market instruments. And investment up to this upper limit is only possible with a single issuer. It is only permitted to invest to this upper limit in a single issuer.

- i) A Sub-fund may not purchase shares in target funds pursuant to 5.3. (d) above "Investments in securities, money market instruments, deposits and derivatives" in excess of 10% of its net assets unless otherwise specified for a Sub-fund in the Special Section.

j)

(A) The Company or management company may not purchase shares for any of the investment funds that it manages that are qualified as UCITS that are linked to a voting right that enables it to exercise an appreciable influence on the management of an issuer.

(B) Furthermore the Company may not purchase more than:

- 10% of the non-voting shares of one and the same issuer;
- 10% of the debentures of one and the same issuer;
- 25% of the shares of one and the same target fund;
- 10% of the money market instruments of one and the same issuer;

The limits provided for under the second, third and fourth dash need not be adhered to when purchasing if the gross amount of the debentures or the money market instruments or the net amount of the shares issued cannot be calculated at the time of acquisition.

Paragraphs (A) and (B) will not be applied:

- to securities and money market instruments issued or guaranteed by a member state of the EU or its central, regional and local authorities;
- to securities and money market instruments issued by a third country;
- to securities and money market instruments issued by international public bodies to which one or more member states of the EU belong;
- to shares which the Company holds in the capital of the company of a third country which primarily invests its assets in securities of issuers that are based in that country, if, because of that country's legislation, such an investment constitutes the only opportunity for the Company to invest in securities of issuers from said country. This exceptional provision shall only however apply subject to the proviso that the company in the third country has an investment policy that does not exceed the limits laid down under (a) to (f) and (i) and (j) (A) and (B). Where limits prescribed under (a) to (f) and (i) are exceeded (k) shall apply mutatis mutandis;
- to shares, held by the Company alone or by the Company and other UCIs in the capital of subsidiaries which carry out certain administrative, advisory or marketing work relating to the redemption of shares as requested by shareholders in the country of the subsidiary only and exclusively for this company or these companies.

k)

(A) The Company need not adhere to the investment limits provided for here in exercising subscription rights linked to securities or money market instruments that form part of its assets. Notwithstanding its obligation to adhere to the principle of risk diversification, the Company may for a period of six months from the time that it was listed depart from the provisions laid down in points (a) to (h).

(B) If the limits referred to in Paragraph (A) are exceeded by the Company unintentionally or as a result of exercising subscription rights it shall endeavour as a primary aim to rectify the situation within the scope of its sale of assets while bearing in mind the interests of the shareholders.

l)

(A) The Company must not take out loans. The Company may however acquire foreign currency by means of a back-to-back loan.

(B) Notwithstanding Paragraph (A), the Company may take up loans for a Sub-fund (i) for up to 10% of its net asset value, provided this is a short-term loan and (ii) equivalent to 10% of its net asset value in the case of loans which facilitate the purchase of property that is used directly to enable it to carry out its work; in no case may these loans and the loans referred to under (i) together exceed 15% of the net asset value in question.

m) The Company or the custodian bank must not issue loans for the account of the Sub-fund or act as a guarantor for third parties, notwithstanding the application of Points (a) to (e) under 5.3 "Investments in securities, money market instruments, deposits and derivatives". This does not conflict with the acquisition by the Company of not yet fully paid-up securities, money market instruments, shares in target funds or not yet fully paid-up financial instruments referred to under (a) and (e) under 5.3 "Investments in securities, money market instruments, deposits and derivatives".

n) The Company or the custodian bank may not conduct any shortselling of securities, money market instruments, units in target funds or financial instruments referred to under (c) and (e) in 5.3 "Investments in securities, money market instruments, deposits and derivatives".

o) The Company may hold liquid funds, which under certain circumstances may be raised to up to 49% of the assets of the Sub-fund in question.

TAX GUIDELINES

It is stated in a specific part of the prospectus that the sub-fund is an equity fund and as such the following conditions in connection with the regulatory investment restrictions specified apply:

A sub-fund is an equity fund if it continually invests at least 51% of its net asset value in equity investments within the meaning of Section 2 (8) of the German Investment Tax Act ("InvStG").

Equity investments in this sense are:

- a) Shares in limited liability companies admitted for trading on a stock exchange or admitted to or included in another organised market;
- b) Shares in limited liability companies which have their registered office in a member state of the European Union or a country in the European Economic Area and are subject in this country to corporate income tax and not exempt from such tax;
- c) Shares in limited liability companies which have their registered office in third country and are subject in this country to corporate income tax of at least 15% and not exempt from such tax;
- d) Units of target funds in the amount of the share of their value as published on each valuation date, in which they actually invest in the aforementioned shares in limited liabilities company, or in the amount of the minimum requirement specified in the investment conditions for the target fund.

Whether a sub-fund qualifies as an equity fund is described in the specific sections.

FURTHER INVESTMENT GUIDELINES

- a) The Company will not invest in securities which involve unlimited liability.
- b) The Fund assets may not be invested in property, precious metals, precious metal contracts, goods or goods contracts.

- c) The Company can undertake further investment restrictions to meet the conditions in those countries in which shares are to be sold.

5.4 INVESTMENT TECHNIQUES AND FINANCIAL INSTRUMENTS

TECHNIQUES FOR EFFICIENT PORTFOLIO MANAGEMENT

In accordance with the Law of 2010, CSSF Circular 14/592 and ESMA guidelines ESMA/2014/937, the Company may, in principle, make use of techniques and instruments relating to money market instruments or securities, provided that these are used for efficient portfolio management and meet the following criteria:

- cost reduction
- reduction of risks
- The generation of addition capital for the Company in accordance with the risk profile of the Company as well as risk diversification rules as described under section 5.3.
- The risks are adequately recorded in the company's risk management process.

The instruments and techniques used will not:

- result in a change in the investment policy of the sub-fund in question
- generate additional risks in comparison to the original risk policy of the company.

EMPLOYING DERIVATIVES

The Company may - subject to a suitable risk management system - invest in those derivatives that are derived from asset items that may be purchased for the Company, or from financial indices, interest rates, exchange rates or currencies. This includes, in particular, options, financial futures contracts and swaps as well as combinations thereof. They may form part the investment strategy in addition to hedging purposes.

Trading in derivatives is conducted within investment limits and serves the efficient management of the Company's investment as well as the maturity management and risk management of the investments.

SWAPS

The Company may, under its investment principles, conclude

- Interest,
- currency,
- equity and
- credit default swap transactions.

Swaps are exchange transactions in which the assets or risks on which the transactions are based are exchanged between the contracting parties.

SWAPTIONS

Swaptions are swaps of options. A swaption is the right, but not the obligation, to enter into a precisely specified swap as far as the conditions are concerned at a particular time or within a particular period.

CREDIT DEFAULT SWAPS

Credit Default Swaps are credit derivatives which enable a potential loan default portfolio to be transferred to others. In return for accepting the loan default risk the seller of the risk pays a premium to the other party.

Apart from this the comments made with regard to swaps apply in a similar fashion.

FINANCIAL INSTRUMENTS CERTIFICATED IN SECURITIES

The Company may also acquire the financial instruments described above if they are certificated in securities. In this respect, transactions relating to financial instruments may also only be partly included in securities (such as warrant-

linked bonds). Comments on opportunities and risks apply similarly to such securitised financial instruments, but with the proviso that the exposure in securitised financial instruments is limited to the value of the security.

LOANS OF SECURITIES

The Board of Directors of the Company has decided not to currently make use of the possibility of securities lending.

In case that the Board of Directors shall decide in the future to make use of this possibility, the Board will decide so in a Board resolution and will adapt the Prospectus respectively.

If the Company decides to lend securities from a Sub-fund to third parties, it will do so as part of a standardised system and taking into account the provisions of CSSF circular 08/356, while bearing in mind however that such transactions may only be conducted through recognized clearing houses such as Euroclear or Clearstream, other nationally recognized clearing centres or through financial institutions with a good credit standing which specialise in these kinds of transactions. The counterparty must also be subject to regulatory provisions which the CSSF regards as equivalent to the provisions of European community law.

The restitution claims must in principle be covered by a guarantee, the value of which at the time the contract is concluded corresponds at least to the entire estimated value of the loaned securities; this can occur for the period of the loan by pledging fixed term deposits or securities, which are issued or guaranteed by OECD member states, their central, regional and local authorities or supranational or regional institutions, and which remain blocked on behalf the company until the loan expires.

This guarantee is not required if the loan is made via Clearstream International S.A. or via any other international company which promises the lender reimbursement of the loaned securities by way of a guarantee or otherwise.

The securities which are accepted by the Company as a loan are not available to the Company, unless they are covered by adequate financial instruments which enable the Company to refund the loaned securities.

The Company may lend securities in connection with the conclusion of a sales transaction under the following circumstances: (x) during a timespan in which the securities have been submitted for registration; and (y) if the securities have been loaned but not promptly returned.

The combined risk exposure to a single counterparty arising from one or more transactions involving loans of securities and/or derivatives and/or repurchase agreements (as described under the "Repurchase agreements" section) must not exceed 10% of the net asset value of the Sub-fund if the counterparty is a financial institution as in Article 41 Paragraph (1) f of the law of 17 December 2010 or 5% of the net asset value in all other cases.

SECURITIES FINANCING TRANSACTIONS

The Company is not authorised to enter into securities lending transactions within the meaning of Regulation (EU) 2015/2365 of the European Parliament and of the Council ("**SFTR**"). Should the Company decide in the future to carry out these types of transactions, the Prospectus will be updated according to the relevant regulations and CSSF circular.

Total Return Swaps

The Company and any Sub-fund may enter into swap contracts relating to any financial instruments or indices, total return swaps and/or other derivatives with similar characteristics ("**TRS**"), for investment purposes and/or efficient portfolio management purposes. TRS involve the exchange of the right to receive the total return, coupons plus capital gains or losses, of a specified reference asset, index or basket of assets against the right to make fixed or floating payments. As such, the use of TRS or other derivatives with similar characteristics allows gaining synthetic exposure to certain markets or underlying assets without investing directly (and/or fully) in these underlying assets.

Cash received by a Sub-fund under a TRS transaction may be held in a cash account with the custodian bank or another bank or credit institution, subject to the conditions of the Law of 17 December 2010.

The counterparties with whom TRS will be concluded will be selected from first-class financial institution specialized in the relevant type of transaction, subject to prudential supervision (such as credit institutions or investment firms) considered by the CSSF as equivalent to those provided by European Union law, be of good reputation and have a minimum rating of BBB. There are no specific requirements as to the legal status (i.e. the corporate form) of the counterparty. The identity of the counterparties will be disclosed in the annual report of the Company.

The counterparties will have no discretion over the composition or management of the portfolio of the Sub-fund or the underlying assets of the TRS.

The entire return generated by a TRS, net of applicable counterparty, brokerage and/or other intermediary fees and expenses in a proportion of up to 100%, will be returned to the respective Sub-fund. The Investment Manager does not charge any fee other than the investment management fee to the Sub-fund upon entering into transactions under total return swap agreements.

TRS may be used in respect of any instrument that is eligible under article 50 of the UCITS Directive.

REPURCHASE AGREEMENTS

The Board of Directors of the Company has decided to currently not make use of repurchase agreements.

In case the Board of Directors shall decide in the future to make use of this possibility, the Board will decide so in a Board resolution and will adapt the Prospectus respectively.

If the Company decides to participate as an accessory in Repurchase Agreements, it will do so subject to the provisions of CSSF Circular 08/356. Repurchase Agreements are transactions, which consist of purchases and sales of securities, in which the agreements grant the purchaser the duty to buy back the securities from the purchaser at a price and within a period agreed between both parties when the contract was concluded. In repurchase agreements the Company may act either as a purchaser or as a seller. Participation in such transactions is however subject to the following guidelines:

- Securities may only be bought or sold through a repurchase agreement if the counterparty is a financial institution with a first-class credit standing specialising in this kind of transaction; the counterparty must also be subject to regulatory provisions which the CSSF regards as equivalent to the provisions of European community law.
- During the term of a repurchase agreement the securities that have been purchased must not be sold before the right to repurchase the securities has been exercised or the repurchase period has expired.
- it is also essential to ensure that the scope of obligations with regard to repurchase agreements is such that the Sub-fund in question can meet its commitments to repurchase shares at any time.
- During the term of the repurchase agreement the combined risk exposure to a single counterparty from one or more transactions, repurchase agreements and/or derivatives and/or securities lending agreements (as described in the chapter "Securities lending" above) may not exceed 10% of the net asset value of the sub-fund if the counterparty is a credit institution as defined in Article 41 (1) of the Law of 2010 or 5% of the net asset values in all other cases.

OTC DERIVATIVE TRANSACTIONS

The Company may conduct both derivative transactions that are licensed for trading at a stock exchange or included in another organised market and also so-called over-the-counter (OTC) transactions.

RISK MANAGEMENT

Risk management procedure is employed within the Company, which enables the management company to monitor and measure the risk associated with the investment positions and their respective proportion of the overall risk profile of the investment portfolio at all times. A procedure is used that permits precise and independent valuation of the OTC derivatives at all times.

The management company monitors the company in accordance with the circular of the *Commission de Surveillance du Secteur Financier* ("CSSF") 11/512 and ensures for the company that the overall risk associated with derivative financial instruments does not exceed 100% of the net assets of a Sub-fund and that as a consequence the risk of each Sub-fund of the company does not in total exceed 200% of the net assets of the Sub-fund in question.

In addition to this the Company is able to borrow 10% of the net assets of a Sub-fund, provided they are temporary loans and these borrowings are not for investment purposes.

A comparatively high aggregate commitment of up to 210% of the net assets can increase both the opportunities and risks of an investment significantly (see in particular information on risk in the section "Risk in connection with derivative transactions").

The risk management procedure applicable for each sub-fund is described in the respective Annex.

COLLATERAL MANAGEMENT FOR TRANSACTIONS WITH OTC DERIVATIVES AND TECHNIQUES FOR EFFICIENT PORTFOLIO MANAGEMENT IN ACCORDANCE WITH THE LAW OF 2010, CSSF CIRCULAR 14/592 AND ESMA GUIDELINES ESMA/2014/937

In cases in which the company carries out transactions in instruments and techniques for the efficient management of the portfolio, collateral used for the purpose of the counterparty risk, must always meet the following criteria:

- a. Liquidity: All collateral accepted which is not in cash must be highly liquid and must be tradeable at a transparent price on a regulated market or within a multi-lateral trading system so that it can be sold at short notice at a price which is close to the valuation established before the sale.
- b. Valuation: Collateral accepted shall be valued at least on every stock exchange day. Assets which show a high degree of price volatility can only be accepted as collateral if suitable conservative valuation discounts (haircuts) are applied.
- c. Issuer rating: The issuer of the accepted collateral has a high credit rating.
- d. Correlation: The collateral accepted by the company is issued by a legal entity which is independent of the counterparty and does not have a high correlation with the performance of the counterparty.
- e. Diversification of collateral: The collateral shall be reasonably diversified in terms of countries, markets and issuers. The criterion of reasonable diversification with respect to issuer concentration is considered to be met if the UCITs receives, as part of efficient portfolio management or transactions with OTC derivatives, a sufficient collateral basket from a counterparty, in which the maximum exposure to a particular issuer corresponds to 20% of the net asset value. If the company has various counterparties, the various collateral basket should be aggregated in order to calculate the 20% limit for the exposure to a single issuer.
- f. Risks in connection with the management of collateral will be controlled and reduced by the risk management department.
- g. In the event of transfers of rights, the collateral accepted shall be held in custody by the company's custodian. For other types of collateral agreements, the collateral shall be held in custody by a third party which is subject to supervision and which is not in any way associated with the issuer of the collateral.
- h. The Company has the option of making use of collateral received at any time, without reference to the counterparty or approval by the counterparty.
- i. Non-cash collateral accepted shall not be sold, re-invested or pledged.
- j. Cash collateral received shall only
 - be invested in sight deposits with legal entities in accordance with Article 50 letter f of Directive 2009/65/EC.
 - In government bonds of high quality.
 - Used for reverse repo transactions provided these are transactions with banks which are subject to supervision and the company is able to request repayment of the full accrued monetary amount.
 - May be invested in money market funds of a short-term duration in accordance with the definition in the CESR guidelines on a common definition for European money market funds.

Newly invested collateral in cash is diversified in accordance with the diversification conditions for non-cash collateral. In accordance with CSSF Circular 14/592 and the ESMA Guidelines (ESMA/2014/937) the SICAV shall create a clear haircut procedure which is adapted to all types of assets accepted as collateral. Any reduction in the value of the corresponding collateral should be lessened through the haircut procedure. The haircut procedure, depending on the type of collateral received, takes into consideration various factors such as currency, price volatility of the assets, maturity, creditworthiness of the issuer etc. No haircut procedure is applied to collateral in cash form. Information on the haircut procedure may be requested from the registered office of the Company.

The following table shows the ranges of the haircuts applied by type of collateral:

Security	Haircut
Cash	0%

Government bonds with a residual maturity <1 year	1%
Government bonds with residual maturities of 1 to 5 years	5%
Government bonds with residual maturities of 5 to 10 years	10%
Government bonds with residual maturities of 10 to 30 years	10%
Government bonds with residual maturities of 30 to 40 years	15%
Government bonds with residual maturities of 40 to 50 years	15%

5.5 GENERAL NOTES ON RISK

Investing in shares involves risks. The risks may include share and bond market risks, interest risk, credit risk, counterparty risk, liquidity and contracting party risks, as well as exchange rate, volatility or political risks or be associated with them.

Each of these risks also arise together with other risks. We will go into some of these risks briefly below. Potential investors should have experience with investments in instruments that are being employed as part of the intended investment policy. Investors should also be aware of the risks associated with investing in shares and not make an investment decision until they have sought comprehensive advice from their legal, tax, financial, accountancy or other advisers on (i) the suitability of any investment in shares bearing in mind their personal, financial and/or tax situation and other circumstances, (ii) the information contained in this Prospectus and (iii) the investment policy of the Company.

It should be borne in mind that investing in a Sub-fund offers both opportunities for increases in equity prices and risks. Shares in the Sub-fund are securities, the value of which is determined by the price fluctuations of the assets included in it. Accordingly, the value of the shares can rise or fall compared with the purchase price.

No assurance can therefore be given that the goals of the investment strategy will be achieved.

Any specific risk information for particular Sub-funds is included in the Special Section. This must be read in connection with this section. The risk information shall in no way be regarded as exhaustive. The investor should consult his personal advisers in order to evaluate the full extent of the risks.

MARKET RISK

The price or market trends of financial products depends in particular on developments in the capital markets, which are again influenced by the general state of the world economy as well as the economic and political conditions in the countries in question. Even irrational factors such as moods, opinions and rumours can have an impact on the general trend in prices, particularly on a stock exchange.

POTENTIAL CONFLICTS OF INTEREST

The management company, custodian bank, the registrar and transfer agent as well as the asset manager, the paying and information agents or sales agents, may, as appropriate, be active as the manager, trustee, fund manager, administrator, registrar and transfer agent or sales agent of funds which pursue similar investment objectives as the company or may be involved in such funds in other ways. It is therefore possible that one of them may be exposed to a potential conflict of interest in relation to the company during the course of their professional activities. Therefore they must always take care individually in such an event that their obligations in each case comply with the management agreement, the central management agreement, the custodian bank agreement, the paying and information agent agreements, the asset management agreement, the registrar and transfer agent agreement as well as sales agent agreements, and endeavour to find an appropriate solution to these conflicts. The management company has set forth

principles in order to endeavour that for all transactions conflicts of interest are avoided in a reasonable manner and, if these cannot be avoided, in order to regulate such conflicts of interest in such a way that the company and its shareholders are treated fairly.

COUNTRY OR TRANSFER RISK

We speak of a country risk if a foreign debtor, in spite of being solvent, cannot make payments promptly or even at all because of a lack of transferability or readiness to do so on the part of his home country. So, for example, payments to which the Company is entitled, may fail to materialise or be made in a currency that is no longer convertible because of foreign exchange restrictions.

SETTLEMENT RISK

Especially when investing in unlisted securities there is a risk that settlement through a transfer system will not be carried out as expected due to a delay in payment or delivery or this failing to take place as agreed.

LEGAL AND TAX RISK

The way in which the Company is treated from a legal and taxation point of view may change in a manner that is both unforeseeable and cannot be influenced. A change resulting from incorrect assessments of taxation requirement by the Company for previous financial years can give rise to a correction that is essentially disadvantageous for the investor, with the result that the investor has to bear the tax burden arising from the correction for preceding financial years, although he may not even have invested in the investment assets at this point in time. On the other hand the investor may fail to enjoy an advantageous correction from the taxation point of view for the present and preceding financial years in which he participated in the investment because he redeemed or sold the shares before the correction in question was implemented.

In addition to this a correction of taxation data can lead to taxable earnings or tax advantages being actually invested from a taxation point of view in a taxation period other than the one that is actually relevant and this can have a negative impact on individual investors.

CURRENCY RISK

Where assets of a Sub-fund are invested in currencies other than that of the Sub-fund currency, the Sub-fund receives the earnings, repayments and proceeds from such investments in the currency in question. If the value of this currency falls compared with the Sub-fund currency, this reduces the value of the Sub-fund.

CUSTODIAL RISK

The custodial risk describes the risk resulting from the essential possibility that investments held in custody might be withdrawn partly or fully from the access of the company to its disadvantage and to the disadvantage of the investors as a result of the insolvency, infringements of a duty of care or misconduct by the custodian or a sub-custodian.

CONCENTRATION RISK

Other risks can arise as a result of concentrating the investment in certain assets or markets. Then the Sub-fund assets are particularly heavily dependent on trends in these assets or markets.

INTEREST RATE CHANGE RISK

Investors should be aware that investing in shares can involve interest risks which may arise if there are fluctuations in the interest rates for the currency applicable to the securities or the Sub-fund of the Company.

POLITICAL RISK / REGULATORY RISK

Investments may be made abroad for a Sub-fund. This involves the risk of disadvantageous international political developments, changes in government policy, taxation and other legal developments.

INFLATION RISK

Inflation poses a devaluation risk for all assets.

CHANGE IN INVESTMENT POLICY

A change in investment policy within the investment spectrum permissible for the Sub-fund may change the content of the risk associated with the Sub-fund's assets.

CREDIT RISK

Investors should be aware that some investments may bear credit risks. Bonds or debt securities bear a credit risk with regard to the issuer for which the credit rating of the issuer can serve as a parameter. Bonds or debt securities floated by issuers with a poorer rating are generally regarded as securities with a higher credit risk and with a higher default probability on the part of the issuer than those securities floated by issuers with a better rating. If an issuer of bonds or debt securities gets into financial or economic difficulties this can have an impact on the value of the bonds or debt securities, (this can fall as low as zero) and the payments made on these bonds or debt securities (these can fall as low as zero).

COUNTERPARTY RISK

Along with the general tendencies in the capital markets the particular trends of the relevant issuers have an impact on the price of an investment. Even if securities are most carefully selected it is for example impossible to rule out losses arising due to the forfeiture of issuers' assets.

RISKS IN CONNECTION WITH DERIVATIVE TRANSACTIONS

The purchase and sale of options along with the conclusion of futures contracts or swaps involve the following risks:

- Changes in the price of the underlying instrument can reduce the value of an option or futures contract all the way down to zero. The Company's investments can also suffer losses as a result of changes in value of the asset underlying a swap.
- Any necessary conclusion of an offsetting transaction (closing out) involves costs.
- The leverage of options can have a stronger impact on the value of investments in a Sub-fund than is the case with a direct purchase of the underlying instruments.
- The purchase of options bears the risk of the option not being exercised because the trend in the prices of the underlying instruments is not as expected so that the option premium paid by the Sub-fund is forfeited. In purchasing options there is a risk that the Sub-fund is committed to accepting assets at a higher price than the current market price or to supplying assets more cheaply than the current market price. The Sub-fund then suffers a loss equivalent to the difference in price minus the option premium earned.
- In the case of futures contracts also there is a risk that the Sub-fund will suffer losses as a result of an unexpected movement in the market price when the contract falls due.

RISKS IN CONNECTION WITH CONTRACTS FOR DIFFERENCE

A contract for difference is an agreement between two parties, namely the buyer and the seller, whereby the seller pays the buyer the difference between the actual price of a certain base value (a security, an instrument, a basket or an index) and the price at a future, to be defined point of time. In case that the difference is negative, the buyer pays the respective difference to the seller.

Such contracts for difference enable investors to acquire synthetic long-positions or short-positions with a variable security base, which, unlike futures, does not have a pre-defined end date or a pre-defined contractual volume. In contrary to investments in securities, the liability of the buyer in a contract for difference transaction goes well beyond the amount paid for the security base.

The Company will, therefore, utilize risk management tools in order to ensure, that it may sell the necessary assets at any time in order to re-pay obligations resulting from redemption requests from such contracts for difference and in order to be able to fulfil other liabilities resulting from such contracts for differences and similar techniques.

RISK ASSOCIATED WITH THE PURCHASE OF SHARES IN INVESTMENT FUNDS

When an investment is made in shares in target funds it should be borne in mind that the fund managers of the individual target funds act independently of one another and that several target funds may therefore pursue similar or opposing investment strategies. Existing risks may accumulate as a result; any opportunities may cancel one another out.

LIQUIDITY RISK

Liquidity risks arise if a specific security is difficult to sell. In principle securities purchased for a Sub-fund should be restricted to those that can be resold at any time. However, difficulties can arise for securities at certain phases or in certain segments of the stock market in selling at the desired time. There is also a risk that securities traded in a somewhat narrow market segment can be subject to considerable price volatility.

COUNTERPARTY CREDIT RISK

In the case of off-exchange OTC ("over the counter") transactions the company may be exposed to risks with regard to the creditworthiness of the other contracting party and its ability to meet the terms of these contracts. And so the Company can for example carry out futures transactions, options and swaps and employ other derivative techniques, in all of which it is subject to the risk of the contracting party failing to meet its obligations arising from the contract in question.

RISKS IN RELATION WITH INVESTMENTS IN SMALL CAP ENTITIES

When investing in small cap entities it needs to be taken into account that shares of such entities may be more difficult to sell. Under extreme market conditions, this may impact the value of the Company and the ability to serve redemption requests.

Investments in small cap entities may lead to higher volatility of the Company.

Investments in Emerging Markets

Investments in Emerging Markets may involve particular risks, for example, from political changes, exchange rate fluctuations, lack of stock-exchange controls, taxes, restrictions on foreign investments and repatriation of funds (transfer risks) and capital markets that may have a lower market capitalisation by international comparison and tend to be volatile and illiquid.

Investments in Russia

Investments in Russia are currently subject to certain elevated risks as regards the ownership and custody of securities. Proof of ownership of Russian securities is established by entry in the books of a company or of its registrar (which is neither an agent of the custodian nor accountable to it). Certificates which evidence ownership of Russian companies are held in custody neither at the custodian nor at their local correspondent bank(s) nor in an effective central custody system. Due to this system and the possibly inefficient or ineffective implementation of government regulations there is a risk that the sub-fund will lose the registration and ownership of Russian securities by fraud, negligence or in another way. In addition, Russian securities are associated with an increased custody risk because, in accordance with current market practice, they are held by Russian institutions which may not have sufficient insurance cover for the damages resulting from theft, destruction or failures while the securities are held in custody.

A sub-fund's investments in transferable securities and money market instruments that are not described may not exceed 10% of the net assets of the relevant sub-fund. For the purposes of this restriction, Russian transferable securities and money market instruments shall in principle be subject to this restriction of 10%, with the exception of transferable securities and money market instruments listed or traded on MICEX-RTS. This stock exchange is a market that has been authorised as a regulated market.

Investments in China via Stock Connect

A sub-fund may invest via the Stock Connect program ("Stock Connect"), either by investing in securities available on Stock Connect ("Stock Connect Securities") or by investing in financial instruments and other market access products on the China A-share market of the People's Republic of China ("China" or "PRC") associated with such Stock Connect Securities.

Stock Connect is a mutual market access program which allows investors in Hong Kong and abroad ("Stock Connect Investors") to trade in selected securities listed on a Chinese stock exchange (currently the Shanghai Stock Exchange and the Shenzhen Stock Exchange "SSE and SZE"). Authorised investors located in China may trade in selected SEHK-listed securities through a platform installed between the Chinese stock exchange and the Stock Exchange of Hong Kong ("SEHK").

As of the date of the Prospectus, the Stock Connect program between Hong Kong and the SSE and the SZE had been developed by, amongst others, SEHK, Hong Kong Securities Clearing Company Limited ("HKSCC") and the China Securities Depository and Clearing Corporation ("ChinaClear"). Stock Connect offers a "northbound link", which allows Stock Connect Investors to buy authorised SSE-listed China A-shares ("SSE Shares") and SZE-listed China A-shares ("SZE Shares") and hold them indirectly ("Northbound Trading"), as well as a "southbound link" through which Chinese investors can buy shares listed on the SEHK and hold them indirectly.

Shareholders should note that Stock Connect is a new trading program. The relevant provisions have not yet been tested and are subject to change, and it cannot be assured that the continued existence of Stock Connect will be authorised. Stock Connect is subject to quota restrictions that may limit the ability of a sub-fund to trade on Stock Connect in a timely manner. This may affect the ability of this sub-fund to effectively implement its investment strategy. The range of securities in Stock Connect is subject to occasional adjustment by the relevant Stock Connect decision-makers (as defined below) (see the following paragraph "Removing Approved Shares and Trading Restrictions"). This may affect the ability of the sub-fund to achieve its investment objective; for example, if a stock that the investment manager wants to buy for a sub-fund is removed from those offered by Stock Connect. In addition, Stock Connect and the technology and the risk management function of the program have only a short history. It is not assured that the systems and controls of the Stock Connect program will function as intended or that they will be adequate.

A) Pre-Trade Checking and Enhanced Pre-Trade Checking

PRC law provides for SSE and SZE to reject a sell order if an investor does not have enough China A-shares available in its account. With respect to a sell order for China A-shares which is not a Stock Connect sell order for the sale of China A-shares held in a special segregated account ("SPSA order"), the SEHK conducts similar checks in connection with all sell orders for Stock Connect Securities via Northbound Trading at the level of the registered stock exchange participant ("Exchange Participant") to ensure that a single Exchange Participant does not make excessive sales ("Pre-Trade Checking"). Enhanced Pre-Trade Checking by the SEHK (or a relevant subsidiary) is done with respect to SPSA orders ("Enhanced Pre-Trade Checking"). In addition, Stock Connect investors must comply with all requirements related to Pre-Trade Checking or Enhanced Pre-Trade Checking that are imposed by the supervisory authority, body or agency ("Stock Connect Decision-Makers") competent or responsible for Stock Connect.

The Pre-Trade Checking requirement may involve the delivery of the Stock Connect Securities by the domestic depository bank or sub-depository bank of a Stock Connect investor to the Exchange Participant that holds these securities in custody in order to ensure that they can be traded on a certain trading day. There is a risk that creditors of the Exchange Participants will attempt to assert that such securities are owned by the Exchange Participant and not to the Stock Connect Investor unless it is clarified that the Exchange Participant acts as the depository bank for such securities in favour of the Stock Connect Investor.

While the Enhanced Pre-Trade Checking model is a positive step towards solving the issue of delivery prior to trading, it is likely that further work and internal and/or regulatory discussions are needed to make this widely acceptable.

As the SSE shares and SZE shares are traded through a broker linked to the Company's sub-depository bank, which is an Exchange Participant as well as a clearing agent for its related broker, no delivery of securities from trading is required, which limits the risk described above.

B) Nominee structure, voting rights and corporate actions

Following settlement by brokers or depositaries as clearing members, SSE shares and SZE shares are held in the Hong Kong Central Clearing and Settlement System ("CCASS"), which is operated by HKSCC as the central securities depository in Hong Kong and as nominee holder. HKSCC is the "nominee holder" of the SSE shares and SZE shares acquired by a Stock Connect investor. While the separate concepts of the nominee holder and the beneficial owner are generally accepted under the Stock Connect provisions of the PRC as well as other laws in mainland China, the application of these rules is untested and it is not assured that the courts of the PRC will recognise these rules; for example, in liquidation proceedings relating to companies in the PRC or other legal proceedings. In the unlikely event that HKSCC is the subject of a winding-up procedure in Hong Kong, investors should note that even under the law of the PRC, SSE shares and SZE shares are not considered part of the general assets of HKSCC which are available for distribution to creditors. Stock Connect investors holding SSE shares and SZE shares (as beneficial owners) generally exercise their rights to the SSE shares and to the SZE shares through HKSCC as the nominee holder. Within the framework of the CCASS rules, HKSCC is willing to support Stock Connect investors by filing a suit in the PRC under certain conditions. Therefore, the Company can only exercise voting rights with respect to SSE shares and SZE shares by giving instructions to HKSCC (via CCASS participants) with respect to voting, and it summarises these instructions in

the form of a single voting instruction to the SSE- and SZE-listed companies. Therefore, the Company may not be able to exercise voting rights in respect of the underlying entity in the same way as in other markets.

In addition, all corporate actions relating to Stock Connect Securities are announced by the issuer through the SSE website and certain officially commissioned newspapers. Stock Connect investors will find the latest announcements on listed companies on the SSE website and in the relevant newspapers. Alternatively, the Hong Kong Exchanges and Clearing Limited website provides information on corporate actions related to Stock Connect Securities from the previous trading day. Issuers listed on the SSE and SZE, however, publish corporate documents exclusively in Chinese and no English translations are available.

In view of the short timeframe within which voting by proxy holders or other measures relating to Stock Connect Securities must be completed, it is not assured that CCASS participants participating in Stock Connect will offer or continue to offer or arrange voting or other related services. Accordingly, it is not assured that the Company will be able to exercise voting rights or participate in the corporate actions with respect to Stock Connect Securities in time or at all.

C) Restriction on day trading

Apart from a few exceptions, day trading is generally not permitted in the China A-stock market. When a sub-fund buys Stock Connect Securities on a trading day (T), the sub-fund may only sell the Stock Connect Securities on or after T+1.

D) Not protected by the Investor Compensation Fund

Investors should note that, when engaging in Northbound Trading, a sub-fund is not protected by the Investor Compensation Fund in Hong Kong or the China Securities Investor Protection Fund and that investors cannot receive compensation through these programs.

E) Quotas applied

If the remaining aggregate quota for Northbound Trading is less than the daily quota, the relevant buy orders are suspended on the next trading day (sell orders are still accepted) until the remaining aggregate quota is again equal to the daily quota. If the daily quota is applied, the acceptance of the corresponding buy orders is also immediately suspended and no further buy orders are accepted for the remainder of the day. Buy orders already accepted are not affected by the application of the daily quota, while sell orders are still accepted. Depending on the aggregate quota status, buy activity will be resumed on the next trading day.

F) Different trading days and trading hours and other operational restrictions

Due to differing holidays between Hong Kong and mainland China or for other reasons, such as unfavourable weather conditions, the trading days and trading hours of the SSE and the SZE and the SEHK may differ. The Stock Connect program only runs on days when both markets are open for trading and when the banks are open in both markets on the relevant settlement days. It may happen that one day is an ordinary trading day for mainland China, but it is not possible to trade China A-shares in Hong Kong. In addition, the SEHK (or any relevant subsidiary) may, under certain circumstances, partially or fully temporarily suspend or restrict the order transfer and the related support services with respect to all or part of Northbound Trading at any time, without notice, as often and for as long as the SEHK deems appropriate.

As a result, there is a risk of price fluctuations of China A-shares during the period when Northbound Trading is suspended or restricted as described above.

G) Removing authorised shares and trading restrictions

A share may be removed from the range of shares eligible for trading via Stock Connect for various reasons, and in this case the share may only be sold, but its purchase is limited. This may affect the ability of a sub-fund to achieve its investment objective. Within the framework of the Stock Connect program, the investment manager may only sell China A-shares and may make no further purchases if: (i) the China A-shares are subsequently no longer included in the relevant indices; (ii) the China A-share is subsequently subject to a "risk warning"; and/or (iii) the corresponding H-share of the China A-share is subsequently no longer traded on the SEHK. There are also price fluctuation limits for China A-shares.

H) Trading costs and taxes

In addition to the payment of trading fees and stamp duties in connection with trading in China A-shares, a sub-fund involved in Northbound Trading may be subject to new sub-fund charges, dividend taxes and taxes on income from file transfer, as determined by relevant authorities.

I) Local market regulations, restrictions on foreign investment and disclosure requirements

Within the framework of Stock Connect, listed China A-corporations and trade in China A-shares are subject to market rules and disclosure requirements for the China A-stock market. Any changes to the rules and regulations of the China A-stock market or the rules relating to Stock Connect may affect share prices. Restrictions on foreign investment and disclosure requirements also apply to China A-shares.

The Company and the investment manager are subject to restrictions on trading in China A-shares (including restrictions on the retention of proceeds) as a result of their investment in China A-shares and are responsible for compliance with all notification, reporting, and other relevant requirements in connection with such investment.

According to current PRC law, once an investor holds 5% of the shares of a PRC listed company, he must disclose his shareholding within three days in accordance with the applicable provisions and he cannot trade in the shares of that company during the reporting period. The investor is also obligated to disclose any change in his holding and to observe the relevant trade restrictions in accordance with PRC law.

In accordance with existing practices in mainland China, as beneficial owner, the Company cannot appoint a proxy to participate in shareholder meetings of Stock Connect China A-shares (see the previous section "Nominee structure, voting rights and corporate actions").

J) Clearing, settlement and custody risks

The HKSCC and ChinaClear have established the clearing link between the two stock exchanges and will each choose a participant in the other exchange in order to facilitate the clearing and settlement of cross-border transactions. For cross-border transactions initiated in a market, the clearing house of this market shall undertake clearing and settlement with its clearing members and undertake to fulfil the clearing and settlement obligations of its clearing participants to the clearing house of the counterparty. Investors from Hong Kong or abroad who have purchased Stock Connect Securities through Northbound Trading should maintain these securities in the share accounts of their brokers or depository banks in CCASS (which is operated by HKSCC).

K) Currency risks

Stock Connect Securities under Northbound Trading are traded and settled in the legal currency of the PRC ("RMB"). If a sub-fund issues unit classes in a currency other than RMB, the sub-fund is exposed to a currency risk due to the necessary conversion of the currency into RMB if the sub-fund invests in a RMB product. The sub-fund also incurs currency conversion costs. Even if the price of the RMB asset remains the same during the purchase and sale or the redemption by the sub-fund, the sub-fund will still incur a loss in the conversion of the redemption/sale proceeds into the local currency if the RMB has lost value.

L) Risk of ChinaClear default

ChinaClear has established a risk management system and measures that have been approved and are supervised by the CSRC. In accordance with the general provisions of the CCASS, the HKSCC will, in the event of the default of ChinaClear (as a central counterparty), in good faith attempt to recover the outstanding Stock Connect Securities and monies through the legal avenues available and, where appropriate, through the liquidation proceedings of ChinaClear. HKSCC shall, for its part, distribute pro rata the Stock Connect Securities and/or monies recovered as directed by the relevant Stock Connect decision-makers and the clearing participants. Stock Connect investors will receive the Stock Connect Securities and/or monies only if they are recovered directly or indirectly by HKSCC. Although the default of ChinaClear is considered highly unlikely, shareholders should be aware of this arrangement and this potential risk.

M) Risk of HKSCC default

If HKSCC fails to meet its obligations or does not meet them on time, this can lead to the inability to settle, or the loss of, Stock Connect Securities and/or monies connected therewith, resulting in losses for the Company.

N) Ownership of Stock Connect Securities

Stock Connect Securities are unsecuritised and are held by HKSCC for their account holders. It is not possible for the Company to physically deposit and withdraw Stock Connect Securities when engaging in Northbound Trading.

The Company's (statutory or equitable or other) ownership rights to Stock Connect Securities are subject to the applicable requirements, including laws relating to the obligation to disclose equity interests or the restriction of foreign investment (see "Local market regulations, restrictions on foreign investment and disclosure requirements"). It has not yet been tested whether the Chinese courts would recognise the ownership of Stock Connect investors, allowing them to file suit against Chinese companies.

O) No manual trading or block trading

There is currently no manual trading or block trading facility for Stock Connect Securities transactions within the scope of Northbound Trading. This may restrict the investment options of a sub-fund.

P) Order sequence

Trade orders are placed in chronological order in the China Stock Connect System ("CSC"). Trade orders cannot be changed, but they can be cancelled and re-placed in the CSC as new orders at the end of the queue. Due to quota restrictions or other market interventions, there is no assurance that transactions executed via a broker will be fulfilled.

Q) Execution problems

Stock Connect transactions may be executed under the Stock Connect rules through one or more brokerage companies that may be appointed by the Company for Northbound Trading. In view of the requirements for Pre-Trade Checking and thus the delivery of Stock Connect Securities to an Exchange Participant prior to the execution of the transaction, the investment manager may determine that it is in the interests of a sub-fund to conduct Stock Connect transactions only via a broker who is linked to the Company's sub-depositary bank, which in turn is an Exchange Participant. In this situation, while the investment manager is aware of its obligations to carry out the execution in the best way possible, it is not able to trade through several brokers, and switching to a new broker requires a corresponding change in the Company's sub-depositary bank arrangements.

R) No off-exchange trading and transfers

Market participants are required to settle, execute or arrange the execution of buy and sell orders or transfer instructions from investors regarding Stock Connect Securities pursuant to Stock Connect rules. This rule against off-exchange trading and transfers for trade in Stock Connect Securities within the scope of Northbound Trading may delay or disrupt the settlement of orders by market participants. However, in order to make the conduct of Northbound Trading and the normal course of business easier for market participants, the off-exchange or "non-trade" transfer of Stock Connect Securities for allocation by fund managers to various funds/sub-funds following the transaction is expressly permitted.

The foregoing may not cover all risks associated with Stock Connect, and the foregoing laws and regulations are subject to change and there is no assurance as to whether or how such changes or developments might limit or affect the Company's investments through Stock Connect.

6. LEGAL MATTERS

6.1 TAX SITUATION

The following summary is based on the law and customs that are currently applied in the Grand Duchy of Luxembourg and are subject to change.

COMPANY

The Company is subject to Luxembourg taxing power. According to Luxembourg law and standard practice the Company is not subject to any income-tax, nor is it subject to any tax on capital appreciation with reference to realised or unrealised valuation gains. No tax is applied in Luxembourg for issuing shares.

The Company is subject to a tax of 0.05% annually on the net asset value, which is declared at the end of the quarter and payable quarterly. Where however portions of the Company's assets are invested in other Luxembourg UCITS, which are taxed, no tax is payable in the Company on these portions.

The net asset value, which constitutes a share category for "institutional investors" pursuant to Luxembourg tax legislation, as defined in the Special Section, is charged a reduced tax of 0.01% per annum, based on the classification of the investors by the Company as institutional investors as defined in the tax legislation. This arrangement is based on

the Company's understanding of the current legal position, which can also be subject to retroactive changes and can also give rise to a retrospective tax charge of 0.05%. The reduced tax may possibly also apply to other share categories.

Capital gains on earnings from dividends, interest and interest payments, which originate in other countries, may also be subject to non-refundable withholding tax or capital gains tax in those countries.

INVESTORS

In accordance with current legislation, investors in Luxembourg are not subject to any income or capital gains or withholding tax with the exception of investors who have their normal place of residence or domicile or are permanently established in Luxembourg.

The OECD has developed a common reporting standard for the automatic exchange of information on financial accounts (common reporting standard – "CRS") in order to make possible the comprehensive and multilateral automatic exchange of information (AEOI) worldwide. On 9 December 2014, Directive 2014/107/EU of the Council amending Directive 2011/16/EU of the Council as regards the mandatory automatic exchange of information in the field of taxation was approved (the "Euro-CRS Directive") in order to enact into law the CRS within the member states. In Austria, the Euro-CRS Directive will apply from 30 September 2018 for the calendar year 2017, meaning the EUSD will apply for one more year.

The Euro-CRS Directive was enacted into Luxembourg law by the Law of 18 December 2015 on the automatic exchange of financial account information in tax matters ("CRS Law").

The CRS Law obliges financial institutions in Luxembourg to identify the owners of financial assets and to determine if they have a tax residence in countries with which Luxembourg has signed an agreement to exchange tax information. In this case, financial institutions in Luxembourg report information on financial accounts of the holders of assets to the Luxembourg tax authorities, which then automatically forward the information to the relevant foreign tax authorities each year.

Accordingly, the Company may request that its investors provide information on the identity and tax residence of the holders of financial accounts to confirm their CRS status (including certain legal entities and their directors) and report this information on shareholders and their accounts to the Luxembourg tax authority (*Administration des Contributions Directes*) if these accounts are considered reportable CRS accounts according to CRS Law. The Company must inform investors that (i) the Company is responsible for the processing of the personal data required according to CRS Law; (ii) the personal data are used exclusively for the purposes specified in the CRS Law; (iii) the personal information may be reported to the Luxembourg tax authority (*Administration des Contributions Directes*); (iv) there is an obligation to respond to CRS-related questions and the Company must provide information on the potential consequences in the event of failure to reply; and (v) the investor has the right to access and rectify data that has been reported to the Luxembourg tax authorities (*Administration des Contributions Directes*).

According to CRS Law, the first information exchange for data for the 2016 calendar year will take place by 30 September 2017. In accordance with the Euro-CRS Directive, the first AEOI between the local tax authorities of the member states for data for the 2016 calendar must take place by 30 September 2017.

In addition, Luxembourg has signed the Multilateral Competent Authority Agreement of the OECD ("Multilateral Agreement") on the automatic exchange of information under the CRS. The objective of the Multilateral Agreement is to introduce the CRS in non-member states, which requires agreements with the individual countries.

The Company reserves the right to refuse applications to subscribe shares if the information provided does not meet the requirements under the CRS Law or the requirements are not met due to such information not being provided.

FOREIGN ACCOUNT TAX COMPLIANCE ACT ("FATCA")

Under the FATCA provisions of the "US Hiring Incentives to Restore Employment Act" ("HIRE") and provided that the Company invests directly or indirectly in US assets, the following income of the Company shall be subject to a 30% US withholding tax, unless the Company meets FATCA requirements: from 31 December 2013, payments made to the Company arising from income generated in the USA; after 31 December 2014, gross income of the Company from sales of land from the USA and, from 31 December 2016, other payments received by the Company.

Compliance with the FATCA provisions can be achieved if the Company concludes a contractual agreement with the US Treasury Department in which the Company agrees to fulfil certain tax publications and withholding tax provisions in the

USA with respect to the shares held and payments to certain investors of the Company, or if the Company is considered to comply with the requirements, provided it is entitled to do so.

It must be noted that the final version of this regulation is not yet made available by the US government and the final detailed rules are not yet finalized. In addition, different governments may enter into bilateral agreements with the US in this connection which may alter the requirements of the FATCA regulations. Amounts, which have been withheld based on the US tax may not be redeemed by the competent US tax authorities, the Internal Revenue Service ("IRS").

Potential investors should consult their advisers as to the applicability of withholding tax regulations, and with respect to the information which may need to be provided and disclosed to the Paying Agent of the Company, and under certain circumstances, the IRS, as prescribed in the final FATCA provisions.

The application of these withholding tax regulations and the rules regarding the transmission of information are currently still uncertain and changes may still occur.

It is incumbent on investors to seek advice on taxation and other consequences brought about by the purchase, ownership, return (redemption), exchange and transfer of shares, including any regulations relating to the monitoring of capital movements.

Holders of Company shares are asked to contact their accountant to obtain information about the relevant applicable taxation of their investment in their country or in any other country.

6.2 ANNUAL GENERAL MEETING AND REPORTING

The Annual General Meeting of the investors of the Company takes place on the second Wednesday in October of each calendar year at 10.00 am in Luxembourg. If this day should not be a banking day in Luxembourg, then the Annual General Meeting will take place on the next banking day in Luxembourg. Other Extraordinary General Meetings of the Company, or meetings of individual Sub-funds or of their share categories, respectively can be held in addition. The invitations to the general meeting and to other meetings are sent in accordance with the law of Luxembourg. They are published in the Mémorial, in the Luxembourg newspaper "Luxemburger Wort" and in other newspapers selected by the Board of Directors. These publications contain information about the place and the time of the general meeting, about the conditions of participation, the agenda as well as the quorum, where required, and the majorities required for the resolutions.

The financial year of the Company starts on the 1st of July and ends on the 30th of June in the following year.

The annual report, which includes the audited consolidated annual statement of accounts of the company, respectively of the Sub-fund, is available no later than fifteen (15) days before the Annual General Meeting at the registered office of the company. Unaudited semi-annual reports are available there within two (2) months of date of the respective half-year period. Copies of these reports are in all cases available from the national representatives as well as from RBC.

In addition to the annual reports and the mid-year reports, which refer to all Sub-funds, separate annual reports and mid-year reports can be prepared for individual Sub-funds.

6.3 APPLICABLE LAW, PLACE OF JURISDICTION

All disputes between the Company, the investors, the custodial bank, the management company, the domicile and principal paying agent, the investment manager / investment advisor as well as the head office, the names register and registration office, the national representatives and the marketing centres are subject to the competent jurisdiction of the Grand Duchy of Luxembourg. The law of Luxembourg applies. With regard to demands by investors from other countries, the aforementioned companies can subject themselves to the jurisdiction of those countries in which shares are offered and sold.

6.4 DOCUMENTS FOR INSPECTION

Copies of the following documents can be inspected during the normal business hours on every banking day in Luxembourg at the registered office of the company in Luxembourg as well as at the pertinent national representatives on their days of business:

- 1a) The investment management contracts, the fund management contract, the contracts with the custodial bank, the head office, the domicile and principal paying agent as well as the names register and registration office. These contracts can be changed by mutual agreement of the contractual parties;

1b) The memorandum of association of the Company.

Upon demand, the following documents can be obtained, free-of-charge:

2a) The KIID and the prospectus;

2b) The last annual and mid-year reports.

In the event of differences between the mentioned documents in German and possible translations, the German version applies. Different mandatory regulations concerning the sale and marketing within the regulatory frameworks in which shares of the Company are legally sold shall apply, irrespective of the above.

6.5 DATA PROTECTION

In accordance with the applicable Luxembourg data protection law and, as of 25 May 2018, Regulation (EU) 2016/679 of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data ("**Data Protection Law**"), the Company acting as data controller (the "**Data Controller**") collects, stores and processes, by electronic or other means, the data provided by the investor at the time of the investment and on an ongoing basis for the purpose of fulfilling the services required by the investor and complying with the Company's legal obligations.

The data processed includes but is not limited to the name, address, e-mail address, bank and financial data, transaction history of each investor, and personally identifiable data ("**Personal Data**").

In case the investor is a legal person, the Company may collect, store and process Personal Data concerning "Controlling Persons" who are natural persons exercising control over the entity investing in Shares of the Company.

Personal Data provided by the investor is processed in order to enter into and subscribe to the Company, for the legitimate interests of the Data Controller, and to comply with the legal obligations imposed on the Data Controller. In particular, the Personal Data provided by the investor is processed for the purposes of (i) subscribing to shares in the Company; (ii) maintaining the share register; (iii) processing investments and withdrawals from, and dividend payments to, the investor; (iv) account administration; (v) opening, closing and blocking of accounts in the name of the shareholders; (vi) sending legal information or notices to the shareholders; and (vii) complying with applicable anti-money laundering rules and other legal obligations, such as maintaining controls in respect of CRS/FATCA obligations. Personal Data are not used for marketing purposes.

Personal Data may also be processed by the Data Controller's data processors (the "**Data Processors**"), which include the Management Company, the Registrar and Transfer Agent, the Domiciliary Agent, the Authorised Independent Auditor and the legal advisors. The Data Processors may, under their own responsibility and only with the prior general authorisation of the Data Controller, disclose Personal Data to their agents and/or delegates (the "**Sub-Data Processors**"), which shall process Personal Data for the sole purposes of assisting the Data Processors in providing their services to the Data Controller and/or assisting the Data Processors in fulfilling their own legal obligations, and in compliance with the same level of protection of Personal Data as applied to the Data Processors.

Personal Data collected may be processed and stored on a cross-border basis within entities located in member states and/or outside the EU, including in countries which are not deemed as equivalent in terms of data protection regulations. If Personal Data is transferred to countries which are not deemed as equivalent in terms of the Data Protection Law, it is legally required that the Company, the Administrative Agent or any other agent has recourse to appropriate safeguards, such as entering into standard contractual clauses approved by the European Commission. The shareholders may obtain a copy of these at the registered office of the Company.

By subscribing to shares of the Company, investors agree to the aforementioned processing of their Personal Data and in particular, the disclosure of their Personal Data to, and the processing of their Personal Data by, the parties referred to above, including subsidiaries situated in countries outside of the EU.

The investor may, at their discretion, refuse to communicate Personal Data to the Company. In this case, however, the Company may reject their request for subscription or holding of shares in the Company, or proceed with the compulsory redemption of all shares already held under the terms and conditions set forth in the Articles of Association and the Prospectus.

Data Processors and Sub-Data Processors may, as the case may be, process Personal Data as Data Processors (when processing Personal Data upon the instruction of the Data Controller), or as distinct Data Controllers (when processing Personal Data for their own purposes, namely fulfilling their own legal obligations). Personal Data may also be

transferred to third parties such as governmental or regulatory agencies, including tax authorities, in accordance with applicable laws and regulations. In particular, Personal Data may be disclosed to the Luxembourg tax authorities which, as Data Controller, may in turn disclose the same information to foreign tax authorities.

Investors agree that the Company will report any relevant information in relation to their investments in the Company to the Luxembourg tax authorities, which will exchange this information on an automatic basis with the competent authorities in accordance with FATCA, the CRS Law or similar laws and regulations in Luxembourg or at EU level.

In accordance with the conditions laid down by the Data Protection Law, the investor acknowledges their right to:

- access their Personal Data;
- correct their Personal Data where it is inaccurate or incomplete;
- object to the processing of their Personal Data;
- request the erasure of their Personal Data;
- request Personal Data portability.

The investor's Personal Data shall not be held for longer than necessary for data processing purposes, in accordance with statutory limitation periods.

Investors can exercise the aforementioned rights by writing to the Data Controller at the Company's registered office.

The investors also acknowledge that they have the right to lodge a complaint with the local competent supervisory authority.

6.6 USE OF BENCHMARKS

Regulation (EU) 2016/1011 of the European Parliament and of the Council of 8 June 2016 on indices used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds and amending Directives 2008/48/EC and 2014/17/EU and Regulation (EU) No 596/2014 (the **Benchmarks Regulation**) entered into force on 1 January 2018.

The Benchmarks Regulation introduces a new requirement for all benchmark administrators that are providers of indices, and that are or are intended to be used as benchmarks in the EU to be authorised or registered by the competent authority. In terms of the sub-funds, the Benchmarks Regulation prohibits the use of benchmarks from EU administrators that are not authorised or registered by the European Securities and Markets Authority (**ESMA**), or that are benchmarks from outside the EU that are not listed in ESMA's public register in accordance with the third country provision under the Benchmarks Regulation.

The Company uses benchmarks within the meaning of the Benchmarks Regulation. Together with the investment manager, the Management Company shall draw up and maintain a written plan outlining the measures to be taken in the event of a significant change to a benchmark, or if a benchmark is discontinued (the "**contingency plan**"). The contingency plan shall be provided to investors free of charge on request at the registered office of the Company.

If a sub-fund uses a benchmark within the meaning of the Benchmarks Regulation, this will be specified in the corresponding Special Section.

Unless otherwise specified in this Prospectus, the indices or benchmarks used by the Fund within the meaning of the Benchmarks Regulation at the time of writing are provided by benchmark administrators that are subject to the transitional provisions under the Benchmarks Regulation. As such, they are not yet listed in ESMA's register of administrators and benchmarks in accordance with Article 36 of the Benchmarks Regulation. These benchmark administrators must have applied for authorisation or registration as an administrator in accordance with the Benchmarks Regulation by 1 January 2020. Up-to-date information on this register should be available by 1 January 2020 at the latest.

7. MARKETING

The Company or the management company may in accordance with the current laws nominate sales offices (sales offices) to offer and sell the shares of each Sub-fund in all countries in which the offering and sale of these shares is

permitted. The sales offices are entitled to retain for themselves the sales charge for the Sub-fund in question that is listed in the Special Section of the prospectus or wholly or partly refrain from doing so.

The Distributors and RBC must at all times be in compliance of the provisions of Luxembourg law on the prevention of money laundering and in particular the Law of 7 July 1989, which amends the Law of 19 February 1973 on the sale of drugs and the fight against drug addiction, the Law of 12 November 2004 on the fight against money laundering and the financing of terrorism and the Law of 5 April 1993 on the financial sector, as amended, and other applicable provisions of the Luxembourg government or regulatory authorities, in particular CSSF Circular 13/556.

The signatories must inter alia submit proof of their identity to the sales office or RBC, which will obtain their signature. The signatories must supply, in accordance with the provisions of Luxembourg law and other relevant provisions of the Luxembourg government or monitoring bodies, all documents and information that is required, such as, for example in the case of individuals, a certified copy of the passport or identity card (certified by an authorised body, such as for example embassy, consulate, notary public, marketing or sales centre or by the local administrative authority), or in the case of companies or other legal entities a certified copy of the certificate of incorporation, the current Articles of Association, a certified copy of the extract from the Register of Companies, a copy of the last published Annual Financial Statement, the full names of the material titleholders (beneficial owners). A list of the necessary documents depending on subscriber status are obtainable from RBC on request.

The sales office and RBC will ensure that the reporting procedure referred to above is strictly adhered to. The Company and the management company may at any time ask the sales office and RBC for an assurance that this procedure is being adhered to. RBC is entitled, without incurring any cost, to suspend or reject subscription or redemption orders if there are any doubts regarding the identity of the applicant due to insufficient, incorrect or lack of identification. The sales centres must also observe all regulations for the prevention of money laundering that are in force in their respective countries.

ANNEX I: SPECIAL SECTION

This Annex (Special Section of the Prospectus) describes the individual Sub-funds and includes the pertinent applicable regulations for these Sub-funds. In the event of changes to the existing Sub-funds, or when setting up new Sub-funds, the Annex will be updated.

1. BELLEVUE FUNDS (LUX) - BB ADAMANT BIOTECH

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit in a targeted way from market trends in specialized markets and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to very high losses in value. In a widely diversified entire portfolio, the Sub-fund can be employed as a supplementary investment.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Biotech is to achieve long-term capital growth by investing at least two-thirds of the net assets of BB Adamant Biotech in a portfolio of carefully chosen shares and other equity securities of companies in the biotechnology industry or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. Without restricting the scope of the term "biotechnology", the companies within the entire value chain in the biotechnology sector consist especially of companies that prepare, develop, utilise, market and/or sell processes, methods, technologies and products in which organisms, cells or cell constituents are used.

In addition, the Company can invest a maximum of one third of the net assets of BB Adamant Biotech in carefully selected shares and other equities from other companies, who have their registered office or carry out the majority of their economic activity in established countries, or in fixed or variable interest bearing securities, convertible and warrant-linked bonds from issuers from established countries.

The Company may invest up to 20% of the net assets of BB Adamant Biotech in Chinese A-shares via Stock Connect.

Up to a maximum 15% of the net assets of BB Adamant Biotech can be invested in warrants on shares or other securities. Purchases of warrants involve higher risks due to the increased volatility of these investments.

The company may in addition hold an adequate level of liquid assets for BB Adamant Biotech.

BB Adamant Biotech is denominated in US dollars.

SPECIAL INVESTMENT RISKS

The investments may be denominated in US dollars or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Adamant Biotech can purchase investments that are issued either by issuers from so-called emerging markets and/or denominated in currencies from emerging markets or are economically linked to currencies from emerging markets. Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Biotech may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) (a) of the Law of 2010 and/or other unlisted securities in order to take advantage of investment opportunities in especially innovative projects in the biotechnology sector.

The assets of BB Adamant Biotech are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BB ADAMANT BIOTECH

Shares	ISIN code	Minimum investment	Currency of the shares	Administration fee	Performance Fee	Initial issue date
I	LU0415392751	--	USD	0.9% p.a.	--	31/03/2009
B	LU0415392322	--	USD	1.6% p.a.	--	31/03/2009
I CHF	LU0415392835	--	CHF	0.9% p.a.	--	02/04/2009
B CHF	LU0415392595	--	CHF	1.6% p.a.	--	02/04/2009
I EUR	LU0415392678	--	EUR	0.9% p.a.	--	02/04/2009
B EUR	LU0415392249	--	EUR	1.6% p.a.	--	02/04/2009
I GBP	LU0767968745	--	GBP	0.9% p.a.	--	30/03/2012
I2 EUR	LU1725387622	5,000,000	EUR	0.8% p.a.	--	30/11/2017

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (Lux) - BB ADAMANT BIOTECH

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

2. BELLEVUE FUNDS (LUX) - BB ADAMANT MEDTECH & SERVICES

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit in a targeted way from market trends in specialized markets and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to losses in value. In a widely diversified portfolio, the Sub-fund can be employed as a supplementary investment.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Medtech & Services is to achieve long-term capital growth by investing at least two-thirds of the net assets of BB Adamant Medtech & Services in a portfolio of carefully chosen shares and other equity securities of companies in the medical technology industry or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. Without restricting the scope of the term “medtech and services”, companies in the medtech and services sector consist of companies primarily engaged in the production, development, funding, marketing and sale of medical devices and the provision of technical medical services, such as hospitals and laboratories, or the facilitation of processes relevant to these facilities; as well as entities primarily engaged in investing in or financing such companies.

In addition, the Company may invest up to one third of the net assets of BB Adamant Medtech & Services in carefully selected shares and other equity securities of other companies which have their registered office or which conduct the majority of their business activities in recognised countries, or invest in fixed-income or floating-rate securities, convertible bonds and bonds with warrants from issuers from recognised countries.

The Company may invest up to 20% of the net assets of BB Adamant Medtech & Services in Chinese A-shares via Stock Connect.

No more than 15% of the net assets of BB Adamant Medtech & Services may be invested in warrants on shares or other equity securities. Purchases of warrants involve higher risks due to the increased volatility of these investments.

The BB Adamant Medtech & Services sub-fund may execute cross-investments in BB Adamant Digital Health

in accordance with the conditions for cross-investments as defined in the General Part of the Prospectus.

In addition, the Company can hold appropriate liquid assets for BB Adamant Medtech & Services.

BB Adamant Medtech & Services is denominated in EUR.

SPECIAL INVESTMENT RISKS

The investments may be denominated in euro or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Adamant Medtech & Services may acquire investments which are issued by issuers from the emerging markets and/or denominated in currencies of emerging markets or are economically linked to currencies of emerging markets. Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Medtech & Services may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) a) of the Law of 2010 and/or other unlisted securities in order to generate added value from especially innovative projects in the medical technology sector.

The assets of BB Adamant Medtech & Services are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BB ADAMANT MEDTECH & SERVICES

Shares	ISIN Code	Minimum investment	Currency of the shares	Administration fee	Performance fee	Initial issue date
I	LU0415391514	--	EUR	0.9% p.a.	--	30/09/2009
AI	TBD	--	EUR	0.9% p.a.	--	Determined by the Board of Directors by circular resolution.
B	LU0415391431	--	EUR	1.6% p.a.	--	30/09/2009
I CHF	LU0415391787	--	CHF	0.9% p.a.	--	30/09/2009
B CHF	LU0415391605	--	CHF	1.6% p.a.	--	30/09/2009
I USD	LU0453818972	--	USD	0.9% p.a.	--	30/09/2009
B USD	LU0453818899	--	USD	1.6% p.a.	--	30/09/2009
T EUR*	LU0433846515	--	EUR	1.2% p.a.	--	28/09/2009
T CHF*	LU0433846606	--	CHF	1.2% p.a.	--	28/09/2009
I GBP	LU0767969719	--	GBP	0.9% p.a.	--	30/03/2012
HB-CHF	LU0580237955	--	CHF	1.6% p.a.	--	31/01/2011
HB-EUR	LU0580275534	--	EUR	1.6% p.a.	--	31/01/2011
I2 EUR	LU1725387895	5,000,000	EUR	0.8% p.a.	--	30/11/2017

* Shares of the T-EUR and T-CHF classes are reserved for investors who are already invested in these classes at the time of receipt of the relevant application for subscription.

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (LUX) - BB ADAMANT MEDTECH & SERVICES

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

3. BELLEVUE FUNDS (LUX) - BB ADAMANT DIGITAL HEALTH

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit in a targeted way from market trends in specialized markets and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to very high losses in value. In a widely diversified entire portfolio, the Sub-fund can be employed as a supplementary investment.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Digital Health is to achieve long-term capital growth by investing at least two-thirds of the net assets of BB Adamant Digital Health in a portfolio of carefully chosen shares and other equity securities of companies whose business activities have a strong focus on the digitisation of the health sector or whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries.

Without limiting the scope of the term Digital Health, businesses in the digital health sector comprise companies that are in a good position in the segments of diagnostics, healthcare IT, life sciences tools, medical technology, healthcare service providers or wellness to be able to benefit from the advent of digital technologies. This allows for new innovative products, treatment methods and services, as well as broad improvement in efficiency across the entire healthcare sector, including in the research and development of medicines.

In addition, the Company may invest no more than one third of the net assets of BB Adamant Digital Health in carefully selected shares and other equity securities from other companies that have their registered office or carry out the majority of their economic activity in recognised countries, or in fixed-income or floating-rate securities, convertible bonds and bonds with warrants from issuers from recognised countries. Depending on market conditions, the sub-fund may derogate temporarily from this equity share, provided that this is in the interests of investors, and invest in money market instruments with an investment grade rating at the time of purchase.

The Company may invest up to 20% of the net assets of BB Adamant Digital Health in Chinese A-shares via Stock Connect.

Up to a maximum 15% of the net assets of BB Adamant Digital Health can be invested in warrants on shares or other securities. Purchases of warrants involve higher risks due to the increased volatility of these investments.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Digital Health may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) (a) of the Law of 2010 and/or other unlisted securities in order to take advantage of investment opportunities in especially innovative projects in the digital health sector.

The Company may in addition hold an adequate level of liquid assets for BB Adamant Digital Health.

BB Adamant Digital Health is denominated in US dollars.

SPECIAL INVESTMENT RISKS

The investments may be denominated in US dollars or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Adamant Digital Health can purchase investments that are issued either by issuers from so-called emerging markets and/or denominated in currencies from emerging markets or are economically linked to currencies from emerging markets. Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

The assets of BB Adamant Digital Health are subject to daily price fluctuations. The value of the sub-fund depends on the daily market value and may therefore rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

BB ADAMANT DIGITAL HEALTH

Shares	ISIN Code	Minimum investment	Currency of the shares	Administration fee	Performance fee	Initial issue date
I	LU1811047247	--	USD	0.9% p.a.	--	30/04/2018
I2	LU1811047320	5,000,000	USD	0.8% p.a.	--	30/04/2018
AI2		5,000,000	USD	0.8% p.a.	--	Determined by the Board of Directors by circular resolution.
B	LU1811047593	--	USD	1.6% p.a.	--	30/04/2018
I CHF	LU1811047676	--	CHF	0.9% p.a.	--	30/04/2018
I2 CHF	LU1811047759	5,000,000	CHF	0.8% p.a.	--	30/04/2018
B CHF	LU1811047833	--	CHF	1.6% p.a.	--	30/04/2018
HB-CHF		--	CHF	1.6% p.a.	--	Determined by the Board of Directors by circular resolution.
I EUR	LU1811047916	--	EUR	0.9% p.a.	--	30/04/2018
I2 EUR	LU1811048054	5,000,000	EUR	0.8% p.a.	--	30/04/2018
B EUR	LU1811048138	--	EUR	1.6% p.a.	--	30/04/2018
HB-EUR		--	EUR	1.6% p.a.	--	Determined by the Board of Directors by circular resolution.

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (LUX) - BB ADAMANT DIGITAL HEALTH

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

4. BELLEVUE FUNDS (LUX) - BB ADAMANT HEALTHCARE INDEX

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit in a targeted way from market trends in specialized markets and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to very high losses in value. In a widely diversified entire portfolio, the Sub-fund can be employed as a supplementary investment.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Healthcare Index is to achieve long-term capital growth by investing at least two-thirds of the net assets of BB Adamant Healthcare Index in a portfolio of carefully chosen shares and other equity securities of companies in the healthcare sector, or companies whose main activity consists in holding stakes in such companies or financing such companies, and that have their registered office or carry out the majority of their economic activity in recognised countries. Without limiting the scope of "healthcare sector", the healthcare sector includes companies from the areas of pharmaceuticals, medical technology, biotechnology and related sectors. In particular, these are companies that create, develop, utilise, market and/or sell processes, methods, technologies, products or services which are used for diagnostic and therapeutic purposes in humans and animals, as well as companies whose activity mainly consists in holding shares in such companies or in financing such companies.

In addition, the Company may invest no more than one third of the net assets of BB Adamant Healthcare Index in carefully selected shares and other equity securities from other companies that have their registered office or carry out the majority of their economic activity in recognised countries, or in fixed-income or floating-rate securities, convertible bonds and bonds with warrants from issuers from recognised countries. Depending on market conditions, the Sub-fund may temporarily deviate from this equity ratio in so far as it is in the interests of investors, and invest in money market instruments with an investment grade rating at the time of purchase.

The Company may invest up to 20% of the net assets of BB Adamant Healthcare Index in Chinese A-shares via Stock Connect.

No more than 15% of the net assets of BB Adamant Healthcare Index may be invested in warrants on shares

or other equity securities. Purchases of warrants involve higher risks due to the increased volatility of these investments.

In addition, the Company can hold appropriate liquid assets for BB Adamant Healthcare Index.

BB Adamant Healthcare Index is denominated in US dollars.

SPECIAL INVESTMENT RISKS

The investments may be denominated in US dollars or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Adamant Healthcare Index can purchase investments that are issued either by issuers from emerging markets and/or denominated in currencies from emerging markets or are economically linked to currencies from emerging markets. Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Healthcare Index may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) (a) of the Law of 2010 and/or other unlisted securities in order to take advantage of investment opportunities in especially innovative projects in the healthcare sector.

The assets of BB Adamant Healthcare Index are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BENCHMARK INDEX

The benchmark index is the Adamant Global Healthcare Index. It replicates the performance of 40 listed shares of the healthcare sector. The four regions of Western Europe, North America, Japan/Australia and the emerging markets are represented by 10 stocks each. The

qualitative aspects include the assessment of the management, product pipeline, operational risks and country risks. The quantitative factors include in particular the assessment of the valuation metrics: price/sales ratio, PEG ratio (PER/earnings growth), EBITDA margin and sales growth of the companies.

The benchmark index currently includes companies that have a market capitalisation of at least USD 400 million and whose securities are in principle freely tradeable. In addition, the average daily trading volume of all shares included in the benchmark index at the time of the half-yearly rebalancing must be at least USD 500,000. The benchmark index is adjusted half-yearly on 20 April and 20 October.

Details on the index are available from S&P Dow Jones Indices.

S&P Dow Jones Indices is the benchmark administrator within the meaning of the Benchmarks Regulation. S&P Dow Jones Indices is not yet listed in ESMA's official register.

BB ADAMANT HEALTHCARE INDEX

Shares	ISIN code	Minimum investment	Currency of the shares	Administratio n fee	Performance Fee	Initial issue date
I	LU1477742818	--	USD	0.9% p.a.	--	31/10/2016
I2	LU1587979177	10,000,000	USD	0.7% p.a.	--	31/03/2017
B	LU1477742909	--	USD	1.6% p.a.	--	31/10/2016
I CHF	LU1477743030	--	CHF	0.9% p.a.	--	31/10/2016
I2 CHF	LU1587979250	10,000,000	CHF	0.7% p.a.	--	31/03/2017
B CHF	LU1477743113	--	CHF	1.6% p.a.	--	31/10/2016
I EUR	LU1477743204	--	EUR	0.9% p.a.	--	31/10/2016
I2 EUR	LU1587979334	10,000,000	EUR	0.7% p.a.	--	31/03/2017
B EUR	LU1477743386	--	EUR	1.6% p.a.	--	31/10/2016

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (Lux) - BB ADAMANT HEALTHCARE INDEX

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach. The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

5. BELLEVUE FUNDS (LUX) - BB ADAMANT EMERGING MARKETS HEALTHCARE

INVESTOR PROFILE

The sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit specifically from the market trends of companies who have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries and who are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to high losses in value.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Emerging Markets Healthcare is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries. The universe for companies is determined cumulatively as follows:

- Shares of companies operating primarily in the healthcare sector of emerging markets.
- These include companies operating in such areas as generics, medtech, biotech, pharma and health services which are involved in the development, manufacture or sale of products and services.
- Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange.

In addition, the Company may invest up to one third of the net assets of BB Adamant Emerging Markets Healthcare in fixed-income or floating-rate securities, convertible bonds and bonds with warrants from issuers from recognised countries.

The Company may invest up to 20% of the net assets of BB Adamant Emerging Markets Healthcare in Chinese A-shares via Stock Connect.

No more than 15% of the net assets of the sub-fund may be invested in warrants on shares or other equity securities.

Purchases of warrants involve higher risks due to the increased volatility of these investments.

In addition, the Company may hold an adequate level of liquid assets for the sub-fund.

BB Adamant Emerging Markets Healthcare is denominated in USD.

SPECIAL INVESTMENT RISKS

The investments may be denominated in US dollars or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

The attention of potential investors is drawn to the fact that investments in BB Adamant Emerging Markets Healthcare are associated with higher risk. Equity markets and the economies of emerging markets are generally volatile. Specifically, the following risks exist:

- a) There may be a low or non-existent trading volume of securities on the relevant securities market, which can lead to liquidity problems and relatively large price fluctuations;
- b) the uncertainty of the political, economic and social conditions and the associated dangers of expropriation or seizure, of unusually high inflation rates, prohibitive tax measures and other negative developments;
- c) potentially serious fluctuations in the foreign exchange rate, different legal frameworks, existing or potential foreign exchange export restrictions, customs or other restrictions and any laws or other restrictions applicable to investments;
- d) political or other situations, which restrict the investment possibilities of BB Adamant Emerging Markets Healthcare, such as restrictions for issuers or industries, which are deemed sensitive in view of the national interests, and
- e) the absence of sufficiently developed legal structures for private or foreign investments and the risk of potentially inadequate safeguards of private property.

Moreover, the sub-fund's investments in certain countries may be negatively affected by political developments and/or changes in legislation, fiscal and currency controls of the particular countries. There are further risks in relation to the settlement of securities transactions, namely the risk that in spite of a payment by the sub-fund, the corresponding securities are delivered late or cannot be delivered. In addition, the risk of securities counterfeiting or securities theft cannot be excluded.

With regard to investments in these emerging market countries, certain risks relating to the ownership and custody of securities must be pointed out.

In some countries, the ownership of securities is established through entries in the books of the company issuing the securities or of its registrar (which is neither an agent of the custodian bank, nor accountable to it). The supervisory obligations of the custodian bank are limited to the best efforts it can reasonably be expected to make.

Share certificates representing stakes in companies in certain countries in the region are not kept by the custodian bank or sub-custodian or an effective central depository system. As a consequence of this system and due to the lack of effective government regulation and enforcement, the Company could lose its registration and ownership of securities in certain countries through fraud, negligence or simply through an oversight. It is also pointed out that such share certificates are generally available only in photocopied form, and their legal value is open to challenge as a result.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Emerging Markets Healthcare may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) (a) of the Law of 2010 and/or other unlisted securities in order to take advantage of investment opportunities in especially innovative projects in the healthcare sector.

The assets of BB Adamant Emerging Markets Healthcare are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 9.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 9.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

PERFORMANCE DEPENDENT ASSET MANAGEMENT FEE

The asset manager of BB Adamant Emerging Markets Healthcare is entitled to a performance-related management fee ("performance fee").

The claim to the performance fee arises when the percentage yield since the start of the calendar year is above that of the benchmark index (outperformance above the benchmark index) indicated below for each sub-fund and, at the same time, the net asset value per share is above the high watermark (outperformance above the high watermark). Both conditions must be fulfilled cumulatively. The performance fee is 10% p.a. of the outperformance above the high watermark, respectively the outperformance above the relevant comparative index, whereby the lower percentage of both such determined out performances is used as the basis for calculating the performance fee.

High watermark: When the Sub-fund, respectively a share category is launched in some other currency to the invoicing currency, the high watermark is identical to the initial issue price. If the net asset value per share on the last valuation day of a subsequent calendar year is above the previous high watermark and the percentage yield in the calendar year is above that of the benchmark index, the high watermark is set at the net asset value calculated before deducting the retained performance fee per share on the last valuation day of that calendar year. In all other cases, the high watermark remains unchanged.

The amount of the performance fee is recalculated on each valuation day, subject to the above-mentioned conditions on the basis of the outperformance since the beginning of the accounting year and is deferred for the relevant sub-fund or share categories. The newly calculated amount for the performance fee is compared on that valuation day with the provision on the previous valuation day. The provision formed on the previous day is suitably adjusted on the basis of the calculated

difference between the newly calculated amount and this provision is adjusted upwards or downwards.

Performance fees calculated in accordance with the above conditions are paid to the investment manager after the end of the calendar year.

This ensures that a performance fee is only paid when the percentage yield of the sub-fund measured in the corresponding share currency for an entire calendar year is above that of the benchmark index (outperformance above the benchmark index) and, at the same time, the net asset value per share is above the high watermark (outperformance above the high watermark).

MSCI is the benchmark administrator of the MSCI Emerging Markets Healthcare Index and is listed in ESMA's official register.

Fund	Share Currency	Comparative Index
BB Adamant Emerging Markets Healthcare	USD	MSCI Emerging Markets Healthcare (M1EF0HC Index) Net TR USD
BB Adamant Emerging Markets Healthcare (EUR)*	EUR	MSCI Emerging Markets Healthcare (M1EF0HC Index) Net TR EUR
BB Adamant Emerging Markets Healthcare (CHF)*	CHF	MSCI Emerging Markets Healthcare (M1EF0HC Index) Net TR CHF

* The Performance Fee is calculated on the basis of the achieved performance of the USD Share Class

BB ADAMANT EMERGING MARKETS HEALTHCARE

Shares	ISIN code	Minimum investment	Currency of the shares	Administration fee	Performance Fee	Initial issue date
I	LU1585228296	--	USD	0.9% p.a.	10% p.a.	31/05/2017
I2	LU1585228379	5,000,000	USD	0.9% p.a.	--	31/05/2017
B	LU1585228452	--	USD	1.6% p.a.	10% p.a.	31/05/2017
I CHF	LU1585228536	--	CHF	0.9% p.a.	10% p.a.	31/05/2017
I2 CHF	LU1585228619	5,000,000	CHF	0.9% p.a.	--	31/05/2017
B CHF	LU1585228700	--	CHF	1.6% p.a.	10% p.a.	31/05/2017
I EUR	LU1585228882	--	EUR	0.9% p.a.	10% p.a.	31/05/2017
I2 EUR	LU1585229005	5,000,000	EUR	0.9% p.a.	--	31/05/2017
B EUR	LU1585229187	--	EUR	1.6% p.a.	10% p.a.	31/05/2017

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (Lux) - BB ADAMANT EMERGING MARKETS HEALTHCARE

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

6. BELLEVUE FUNDS (LUX) - BB ADAMANT ASIA PACIFIC HEALTHCARE

INVESTOR PROFILE

The sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit specifically from the market trends of companies who have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region and who are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to high losses in value.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Asia Pacific Healthcare is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of the Asia-Pacific region. The universe for companies is determined cumulatively as follows:

- Shares of companies that have their registered office or carry out the majority of their economic activity in the healthcare sector in the Asia-Pacific region.
- These include companies operating in such areas as generics, medtech, biotech, pharma and health services which are involved in the development, manufacture or sale of products and services.
- Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange.

In addition, the Company may invest no more than one third of the net assets of BB Adamant Asia Pacific Healthcare in fixed-income or floating-rate securities, convertible bonds and bonds with warrants from issuers from recognised countries.

The Company may invest up to 20% of the net assets of BB Adamant Asia Pacific Healthcare in Chinese A-shares via Stock Connect.

No more than 15% of the net assets of the sub-fund may be invested in warrants on shares or other equity securities.

Purchases of warrants involve higher risks due to the increased volatility of these investments.

In addition, the Company may hold an adequate level of liquid assets for the sub-fund.

BB Adamant Asia Pacific Healthcare is denominated in USD.

SPECIAL INVESTMENT RISKS

The investments may be denominated in US dollars or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

The attention of potential investors is drawn to the fact that investments in BB Adamant Asia Pacific Healthcare are associated with higher risk. Equity markets and the economies of emerging markets are generally volatile. Specifically, the following risks exist:

- a) There may be a low or non-existent trading volume of securities on the relevant securities market, which can lead to liquidity problems and relatively large price fluctuations;
- b) the uncertainty of the political, economic and social conditions and the associated dangers of expropriation or seizure, of unusually high inflation rates, prohibitive tax measures and other negative developments;
- c) potentially serious fluctuations in the foreign exchange rate, different legal frameworks, existing or potential foreign exchange export restrictions, customs or other restrictions and any laws or other restrictions applicable to investments;
- d) political or other situations, which restrict the investment possibilities of the BB Adamant Asia Pacific Healthcare, such as restrictions for issuers or industries, which are deemed sensitive in view of the national interests, and
- e) the absence of sufficiently developed legal structures for private or foreign investments and the risk of potentially inadequate safeguards of private property.

Moreover, the sub-fund's investments in certain countries may be negatively affected by political developments and/or changes in legislation, fiscal and currency controls of the particular countries. There are further risks in relation to the settlement of securities transactions, namely the risk that in spite of a payment by the sub-fund, the corresponding securities are delivered late or cannot be delivered. In addition, the risk of securities counterfeiting or securities theft cannot be excluded.

With regard to investments in these emerging market countries, certain risks relating to the ownership and custody of securities must be pointed out.

In some countries, the ownership of securities is established through entries in the books of the company issuing the securities or of its registrar (which is neither an agent of the custodian bank, nor accountable to it). The supervisory obligations of the custodian bank are limited to the best efforts it can reasonably be expected to make.

Share certificates representing stakes in companies in certain countries in the region are not kept by the custodian bank or sub-custodian or an effective central depository system. As a consequence of this system and due to the lack of effective government regulation and enforcement, the Company could lose its registration and ownership of securities in certain countries through fraud, negligence or simply through an oversight. It is also pointed out that such share certificates are generally available only in photocopied form, and their legal value is open to challenge as a result.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Asia Pacific Healthcare may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) (a) of the Law of 2010 and/or other unlisted securities in order to take advantage of investment opportunities in especially innovative projects in the healthcare sector.

The assets of BB Adamant Asia Pacific Healthcare are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 9.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 9.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

PERFORMANCE DEPENDENT ASSET MANAGEMENT FEE

The asset manager of BB Adamant Asia Pacific Healthcare is entitled to a performance-related management fee ("performance fee").

The claim to the performance fee arises when the percentage yield since the start of the calendar year is above that of the benchmark index (outperformance above the benchmark index) indicated below for each sub-fund and, at the same time, the net asset value per share is above the high watermark (outperformance above the high watermark). Both conditions must be fulfilled cumulatively. The performance fee is 10% p.a. of the outperformance above the high watermark, respectively the outperformance above the relevant comparative index, whereby the lower percentage of both such determined out performances is used as the basis for calculating the performance fee.

High watermark: When the Sub-fund, respectively a share category is launched in some other currency to the invoicing currency, the high watermark is identical to the initial issue price. If the net asset value per share on the last valuation day of a subsequent calendar year is above the previous high watermark and the percentage yield in the calendar year is above that of the benchmark index, the high watermark is set at the net asset value calculated before deducting the retained performance fee per share on the last valuation day of that calendar year. In all other cases, the high watermark remains unchanged.

The amount of the performance fee is recalculated on each valuation day, subject to the above-mentioned conditions on the basis of the outperformance since the beginning of the accounting year and is deferred for the relevant sub-fund or share categories. The newly calculated amount for the performance fee is compared on that valuation day with the provision on the previous valuation day. The provision formed on the previous day is suitably adjusted on the basis of the calculated difference between the newly calculated amount and this provision is adjusted upwards or downwards.

Performance fees calculated in accordance with the above conditions are paid to the investment manager after the end of the calendar year.

This ensures that a performance fee is only paid when the percentage yield of the sub-fund measured in the corresponding share currency for an entire calendar year is above that of the benchmark index (outperformance above the benchmark index) and, at the same time, the net asset value per share is above the high watermark (outperformance above the high watermark).

MSCI is the benchmark administrator of the MSCI Asia Pacific Healthcare Index and is listed in ESMA's official register.

BB Adamant Asia Pacific Healthcare	USD	MSCI Asia Pacific Healthcare (M1PF0HC Index) Net TR USD
BB Adamant Asia Pacific Healthcare (EUR)*	EUR	MSCI Asia Pacific Healthcare (M1PF0HC Index) Net TR EUR
BB Adamant Asia Pacific Healthcare (CHF)*	CHF	MSCI Asia Pacific Healthcare (M1PF0HC Index) Net TR CHF

* The Performance Fee is calculated on the basis of the achieved performance of the USD Share Class

Fund	Share Currency	Comparative Index
------	----------------	-------------------

BB ADAMANT ASIA PACIFIC HEALTHCARE

Shares	ISIN code	Minimum investment	Currency of the shares	Administration fee	Performance Fee	Initial issue date
I	LU1587984680	--	USD	0.9% p.a.	10% p.a.	28/04/2017
I2	LU1587984763	5,000,000	USD	0.9% p.a.	--	28/04/2017
AI2	TBD	5,000,000	USD	0.9% p.a.	--	Determined by the Board of Directors by circular resolution.
B	LU1587984847	--	USD	1.6% p.a.	10% p.a.	28/04/2017
I CHF	LU1587984920	--	CHF	0.9% p.a.	10% p.a.	28/04/2017
I2 CHF	LU1587985067	5,000,000	CHF	0.9% p.a.	--	28/04/2017
B CHF	LU1587985141	--	CHF	1.6% p.a.	10% p.a.	28/04/2017
I EUR	LU1587985224	--	EUR	0.9% p.a.	10% p.a.	28/04/2017
I2 EUR	LU1587985497	5,000,000	EUR	0.9% p.a.	--	28/04/2017
B EUR	LU1587985570	--	EUR	1.6% p.a.	10% p.a.	28/04/2017

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (Lux) - BB ADAMANT ASIA PACIFIC HEALTHCARE

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

7. BELLEVUE FUNDS (LUX) - BB ADAMANT SUSTAINABLE HEALTHCARE

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit in a targeted way from market trends in specialized markets and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to very high losses in value. In a widely diversified entire portfolio, the Sub-fund can be employed as a supplementary investment.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Adamant Sustainable Healthcare is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies in the healthcare sector taking account of sustainability criteria. The fund can also invest in companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. Without limiting the scope of "healthcare sector", the healthcare sector includes companies from the areas of pharmaceuticals, medical technology, biotechnology and related sectors. In particular, these are companies that create, develop, utilise, market and/or sell processes, methods, technologies, products or services which are used for diagnostic and therapeutic purposes in humans and animals, as well as companies whose activity mainly consists in holding shares in such companies or in financing such companies.

The fund is managed taking sustainability criteria into consideration. This means that according to generally accepted approaches, environmental (ecological), social, societal, ethical and corporate governance criteria (ESG/CSR) are taken into account in the assessment and selection of a company for the portfolio. The selection of securities takes account of both exclusion criteria (negative selection) and the "best in class" method (positive selection) in selecting particularly sustainable companies in each sector. In addition, selection also takes account of impact criteria with regard to the United Nations' Sustainable Development Goals (UN SDG). Exclusion criteria and best in class ESG/CSR criteria go by the following guidelines:

- Austrian Environmental Authority guidelines
- Guidelines for ethical sustainable investments in the Protestant Church

- Orientation guidelines from the Catholic Church on "ethical sustainable investment"
- Principles of the United Nations Global Compact

These criteria relate, as far as is applicable, to companies in the healthcare sector, to the following issues, among others:

- Environment: protecting natural resources, the atmosphere and inland waters; limiting land degradation and climate change; preventing interference in the ecosystem and loss of biodiversity
- Social: mandatory non-discrimination; general human rights; prohibition of child and forced labour; product safety; health and safety in the workplace; fair working conditions and appropriate compensation
- Corporate principles: anti-corruption principles in accordance with the UN Global Compact

In addition, the Company may invest no more than one third of the net assets of BB Adamant Sustainable Healthcare in carefully selected shares and other equity securities from other companies that have their registered office or carry out the majority of their economic activity in recognised countries, or in fixed-income or floating-rate securities, convertible bonds and bonds with warrants from issuers from recognised countries. Depending on market conditions, the Sub-fund may temporarily deviate from this equity ratio in so far as it is in the interests of investors, and invest in money market instruments with an investment grade rating at the time of purchase.

Up to a maximum 15% of the net assets of BB Adamant Sustainable Healthcare can be invested in warrants on shares or other securities. Purchases of warrants involve higher risks due to the increased volatility of these investments.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Adamant Sustainable Healthcare may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) (a) of the Law of 2010 and/or other unlisted securities in order to take advantage of investment opportunities in especially innovative projects in the healthcare sector.

The company may in addition hold an adequate level of liquid assets for BB Adamant Sustainable Healthcare.

BB Adamant Sustainable Healthcare is denominated in US dollars.

SPECIAL INVESTMENT RISKS

The investments may be denominated in US dollars or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Adamant Sustainable Healthcare can purchase investments that are issued either by issuers from so-called emerging markets and/or denominated in currencies from emerging markets or are economically linked to currencies from emerging markets. Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

The assets of BB Adamant Sustainable Healthcare are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BB ADAMANT SUSTAINABLE HEALTHCARE

Shares	ISIN-Code	Minimum investment	Currency of the shares	Administration fee	Performance fee	Initial issue date
I	LU1819585370	--	USD	0.9% p.a.	--	29/06/2018
I2	LU1819585453	5,000,000	USD	0.8% p.a.	--	29/06/2018
B	LU1819585537	--	USD	1.6% p.a.	--	29/06/2018
I CHF	LU1819585610	--	CHF	0.9% p.a.	--	29/06/2018
I2 CHF	LU1819585701	5,000,000	CHF	0.8% p.a.	--	29/06/2018
B CHF	LU1819585883	--	CHF	1.6% p.a.	--	29/06/2018
I EUR	LU1819586006	--	EUR	0.9% p.a.	--	29/06/2018
I2 EUR	LU1819586188	5,000,000	EUR	0.8% p.a.	--	29/06/2018
AI2 EUR	TBD	5,000,000	EUR	0.8% p.a.	--	Determined by the Board of Directors by circular resolution.
B EUR	LU1819586261	--	EUR	1.6% p.a.	--	29/06/2018

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (Lux) - BB ADAMANT SUSTAINABLE HEALTHCARE

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach. The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

8. BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR EUROPE

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit specifically from market trends in family controlled European companies and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to high losses in value.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Entrepreneur Europe is to achieve long-term capital growth by investing at least two-thirds of the net assets of BB Entrepreneur Europe in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in recognised European countries and are mainly managed by owners. The universe for owner-managed companies is determined as follows:

- One or more shareholders have significant shareholdings (at least 20%) and have a decisive influence on the corporate policy.
- Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange.

In addition, the company may invest no more than one-third of the net assets of BB Entrepreneur Europe in fixed-income or floating-rate securities and convertible bonds and bonds with warrants from issuers from recognised countries.

No more than 15% of the net assets of BB Entrepreneur Europe may be invested in warrants on shares or other equity securities. Purchases of warrants involve higher risks due to the increased volatility of these investments.

Purchases of warrants involve higher risks due to the increased volatility of these investments.

The BB Entrepreneur Europe may execute cross-investments in BB Entrepreneur Europe Small in accordance with the conditions for cross-investments as defined in the General Part of the Prospectus.

BB Entrepreneur Europe is denominated in EUR.

SPECIAL INVESTMENT RISKS

The investments may be denominated in euro or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Entrepreneur Europe may acquire investments which are issued by issuers from European emerging markets and/or denominated in currencies of European emerging markets or are economically linked to currencies of emerging markets.

Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Entrepreneur Europe may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

In accordance with Article 41 (2) a) of the Law of 2010, the Sub-fund can invest a maximum 10% of its net assets in securities and/or other unlisted securities.

The assets of BB Entrepreneur Europe are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BB ENTREPRENEUR EUROPE

Shares	ISIN Code	Minimum investment	Currency of the shares	Administration fee	Performance Fee	Initial issue date
I	LU0415391944	--	EUR	0.9% p.a.	--	30/04/2009
AI	TBD	--	EUR	0.9% p.a.	--	Determined by the Board of Directors by circular resolution.
B	LU0415391860	--	EUR	1.6% p.a.	--	30/04/2009
I CHF	LU0415392165	--	CHF	0.9% p.a.	--	30/04/2009
B CHF	LU0415392082	--	CHF	1.6% p.a.	--	30/04/2009
I GBP	LU0767970303	--	GBP	0.9% p.a.	--	30/03/2012
AB EUR	LU0810317205	--	EUR	1.6% p.a.	--	31/07/2012
I2 EUR	LU1725387978	5,000,000	EUR	0.8% p.a.	--	30/11/2017

RISK MANAGEMENT OF THE SUB-FUND BB ENTREPRENEUR EUROPE:

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

9. BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR EUROPE SMALL

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit specifically from market trends in small and middle capitalized and family controlled European companies and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to high losses in value.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Entrepreneur Europe Small is the achievement of long-term capital growth by investing at least two thirds of the net assets of BB Entrepreneur Europe Small in a portfolio of carefully chosen shares and other equities of small and middle capitalized companies, who have their registered office or carry out the majority of their economic activity in established European countries and are mainly managed by the owners. The universe for owner-managed companies is determined as follows:

- One or more shareholders have significant shareholdings (at least 20%) and have a decisive influence on the corporate policy.
- Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange.

In addition, the Company can invest up to a maximum of one third of the net assets of BB Entrepreneur Europe Small in fixed or variable interest bearing securities, convertible and warrant-linked bonds from issuers from established countries.

No more than 15% of the net assets of BB Entrepreneur Europe may be invested in warrants on shares or other equity securities. Sub-funds may be invested in warrants on shares or other equity securities.

Purchases of warrants involve higher risks due to the increased volatility of these investments.

In addition, the Company can maintain appropriate liquid assets for BB Entrepreneur Europe Small.

The BB Entrepreneur Europe Small may execute cross-investments in BB Entrepreneur Europe in accordance with the conditions for cross-investments as defined in the General Part of the Prospectus.

BB Entrepreneur Europe Small is issued in Euro.

SPECIAL INVESTMENT RISKS

The investments may be denominated in euro or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

BB Entrepreneur Europe Small can purchase investments that are issued either by issuers from European emerging markets and/or denominated in currencies from European emerging markets or are economically linked to currencies from emerging markets.

Emerging markets generally refers to the markets of countries that are developing into modern industrialised countries and therefore have a high growth potential, but also entail higher risks. These include in particular the countries included in the International Finance Corporation Global Composite Index or in the MSCI Emerging Markets Index.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Entrepreneur Europe Small may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

In accordance with Article 41 (2) a) of the Law of 2010, the Sub-fund can invest a maximum 10% of its net assets in securities and/or other unlisted securities.

The assets of BB Entrepreneur Europe Small are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

PERFORMANCE FEE

The investment manager of BB Entrepreneur Europe Small is entitled to a performance fee.

The claim to the performance fee arises when the percentage yield since the start of the calendar year is above that of the benchmark index (outperformance above the benchmark index) indicated below for each sub-fund and, at the same time, the net asset value per share is above the high watermark (outperformance above the high watermark). Both conditions must be fulfilled cumulatively. The performance fee is 10% p.a. of the outperformance above the high watermark, respectively the outperformance above the relevant comparative index, whereby the lower percentage of both such determined out performances is used as the basis for calculating the performance fee.

High watermark: If the net asset value per share on the last valuation day of a subsequent calendar year is above the previous high watermark and the percentage yield in the calendar year is above that of the benchmark index, the high watermark is set at the net asset value calculated before deducting the retained performance fee per share on the last valuation day of that calendar year. In all other cases, the high watermark remains unchanged.

The amount of the performance fee is recalculated on each valuation day, subject to the above-mentioned conditions on the basis of the outperformance since the beginning of the accounting year and is deferred for the relevant sub-fund or share categories. The newly calculated amount for the performance fee is compared on that valuation day with the provision on the previous valuation day. The provision formed on the previous day is suitably adjusted on the basis of the calculated difference between the newly calculated amount and this provision is adjusted upwards or downwards.

Performance fees calculated in accordance with the above conditions are paid to the investment manager after the end of the calendar year.

This ensures that a performance fee is only paid when the percentage yield of the sub-fund measured in the corresponding share currency for an entire calendar year is above that of the benchmark index (outperformance above the benchmark index) and, at the same time, the net asset value per share is above the high watermark (outperformance above the high watermark).

MSCI is the benchmark administrator of the MSCI Europe ex UK Small Index and is listed in ESMA's official register.

Fund	Share Currency	Comparative Index
BB Entrepreneur Europe Small*	EUR	MSCI Europe ex UK Small Net TR EUR
BB Entrepreneur Europe Small*	CHF	MSCI Europe ex UK Small Net TR in CHF

* The Performance Fee is calculated on the basis of the achieved performance of the USD Share Class

BB ENTREPRENEUR EUROPE SMALL

Shares	ISIN code	Minimum investment	Currency of the shares	Administration fee	Performance Fee	Initial issue date
I	LU0631859062	--	EUR	0.9% p.a.	10% p.a.	30/06/2011
B	LU0631859229	--	EUR	1.6% p.a.	10% p.a.	30/06/2011
I CHF	LU0631859575	--	CHF	0.9% p.a.	10% p.a.	30/06/2011
B CHF	LU0631859732	--	CHF	1.6% p.a.	10% p.a.	30/06/2011
I2 EUR	LU1725388190	5,000,000	EUR	0.8% p.a.	10% p.a.	30/11/2017
HI CHF	LU1986980750	--	CHF	0.9% p.a.	10% p.a.	23/04/2019

RISK MANAGEMENT OF THE SUB-FUND BB ENTREPRENEUR EUROPE SMALL:

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

10. BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR SWISS SMALL&MID

INVESTOR PROFILE

The sub-fund is only suitable for experienced investors who have experience with volatile investments, have in-depth knowledge of the capital markets and wish to profit specifically from market trends in businesses, as described in the investment policy, and are familiar with the opportunities and risks specific to this market segment. Investors need to expect fluctuations in value, which can also lead temporarily to high losses in value.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB Entrepreneur Swiss Small&Mid is to achieve long-term capital growth by investing at least two thirds of the net assets of BB Entrepreneur Swiss Small&Mid in a portfolio of carefully chosen shares and other equity securities of small and medium sized companies that either (i) have their registered office in Switzerland (ii) have their registered office outside of Switzerland but carry out the majority of their economic activity Switzerland or (iii) are holding companies that mainly hold investments in companies whose registered office is in Switzerland and which are mainly managed by the owners. The universe for owner-managed companies is determined as follows:

- One or more shareholders have significant shareholdings (at least 20%) and have a decisive influence on the corporate policy.
- Listed on a recognised stock market or, in the case of an initial public offering, the company has applied for listing on the relevant exchange.

In addition, the Company can invest up to a maximum of one third of the net assets of BB Entrepreneur Swiss Small&Mid in fixed or variable interest bearing securities, as well as convertible and warrant-linked bonds from issuers from recognised countries.

No more than 15% of the net assets of BB Entrepreneur Swiss Small&Mid may be invested in warrants on shares or other equity securities. BB Entrepreneur Swiss Small&Mid may be invested in warrants on shares or other equity securities.

Purchases of warrants involve higher risks due to the increased volatility of these investments.

In addition, the Company can hold appropriate liquid assets for BB Entrepreneur Swiss Small&Mid.

BB Entrepreneur Swiss Small&Mid is denominated in CHF.

SPECIAL INVESTMENT RISKS

The investments can be in CHF or in other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

Subject to being compliant with the limits and conditions defined by the CSSF, BB Entrepreneur Swiss Small&Mid may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

In accordance with Article 41 (2) a) of the Law of 2010, the Sub-fund can invest a maximum 10% of its net assets in securities and/or other unlisted securities.

The assets of BB Entrepreneur Swiss Small&Mid are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BB ENTREPRENEUR SWISS SMALL&MID

Shares	ISIN code	Minimum investment	Currency of the shares	Administration fee	Performance Fee	Initial issue date
I	LU1477743469	--	CHF	0.9% p.a.	--	30/11/2016
B	LU1477743543	--	CHF	1.6% p.a.	--	30/11/2016
I	LU1477743626	--	EUR	0.9% p.a.	--	30/11/2016
B	LU1477743899	--	EUR	1.6% p.a.	--	30/11/2016
I2 CHF	LU1725388356	5,000,000	CHF	0.7% p.a.	--	30/11/2017

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (LUX) - BB ENTREPRENEUR SWISS SMALL&MID

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

11. BELLEVUE FUNDS (LUX) - BB AFRICAN OPPORTUNITIES

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors who have experience with volatile investments, in-depth knowledge of capital markets and intend to profit in a targeted manner from the market trends of companies who have their registered office or carry out the majority of their economic activity in African countries, including the Gulf Cooperation Council countries, and are familiar with the specific opportunities and risks of these market segments. Investors need to expect fluctuations in value, which can also lead temporarily to high losses in value.

INVESTMENT OBJECTIVES AND POLICY

The sub-fund is an equity fund.

The investment objective of BB African Opportunities is to achieve long-term capital growth by investing at least two-thirds of the net assets of BB African Opportunities in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in African countries, including the Gulf Cooperation Council countries.

In addition, the Company can invest up to a maximum of one third of the net assets of BB African Opportunities in fixed or variable interest bearing securities, convertible and warrant-linked bonds from issuers from established countries.

Up to a maximum 15% of the net assets of BB African Opportunities can be invested in warrants on shares or other securities.

Purchases of warrants involve higher risks due to the increased volatility of these investments.

In addition, the Company can maintain appropriate liquid assets for BB African Opportunities.

BB African Opportunities is issued in EUR.

SPECIAL INVESTMENT RISKS

The investments may be denominated in euro or other currencies. Foreign currency risks may be fully or partially hedged. A drop in value due to currency fluctuations cannot be ruled out.

It is pointed out to potential investors that investments in BB African Opportunities involve a higher risk. Stock markets and economies in African countries are generally volatile. Specifically, the following risks exist:

- a) There may be a low or non-existent trading volume of securities on the relevant securities market, which

can lead to liquidity problems and relatively large price fluctuations;

- b) the uncertainty of the political, economic and social conditions and the associated dangers of expropriation or seizure, of unusually high inflation rates, prohibitive tax measures and other negative developments;
- c) potentially serious fluctuations in the foreign exchange rate, different legal frameworks, existing or potential foreign exchange export restrictions, customs or other restrictions and any laws or other restrictions applicable to investments;
- d) political or other situations, which restrict the investment possibilities of the BB African Opportunities, such as restrictions for issuers or industries, which are deemed sensitive in view of the national interests, and
- e) the absence of sufficiently developed legal structures for private or foreign investments and the risk of potentially inadequate safeguards of private property.

Moreover, the sub-fund's investments in certain countries may be negatively affected by political developments and/or changes in legislation, fiscal and currency controls of the particular countries. There are further risks in relation to the settlement of securities transactions, namely the risk that in spite of a payment by the sub-fund, the corresponding securities are delivered late or cannot be delivered. In addition, the risk of securities counterfeiting or securities theft cannot be excluded.

With regard to investments in specific African countries, reference is made to specific risks regarding the ownership and safekeeping of securities.

In some African countries, the ownership of securities is verified through entries in the books of the company issuing the securities or their registration office (which is not an agent of the custodian depot, nor is it responsible towards it). The supervisory obligations of the custodian bank are limited to the best efforts it can reasonably be expected to make.

Share certificates that represent holdings in companies in specific African countries, including gulf co-operation countries, are not kept at the custodian bank or the sub-custodian bank or in an effective central custodian system. Due to this system and due to the lack of effective national regulations and enforceability, the Company could lose its registration and ownership of securities in some African countries, including gulf co-operation countries, due to fraud, negligence or by simply being overlooked. It is also pointed out that such share

certificates are generally available only in photocopied form, and their legal value is open to challenge as a result.

Subject to being compliant with the limits and conditions defined by the CSSF, BB African Opportunities may use derivative instruments in order to achieve an efficient portfolio management, in particular also for hedging purposes.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The sub-fund may invest up to 10% of its net assets in securities in accordance with Article 41 (2) a) of the Law of 2010 and/or other unlisted securities.

The assets of BB African Opportunities are subject to daily price fluctuations. The value of the sub-fund depends on the daily stock market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

BB AFRICAN OPPORTUNITIES

Shares	ISIN code	Minimal initial investment	Currency of the shares	Administratio n fee	Performance Fee	Initial issue date
I	LU0433847323	--	EUR	0.9% p.a.	--	30/06/2009
B	LU0433847240	--	EUR	1.6% p.a.	--	30/06/2009
I CHF	LU0433847679	--	CHF	0.9% p.a.	--	30/06/2009
B CHF	LU0433847596	--	CHF	1.6% p.a.	--	30/06/2009
I USD	LU0437409203	--	USD	0.9% p.a.	--	30/06/2009
B USD	LU0437409112	--	USD	1.6% p.a.	--	30/06/2009
I GBP	LU0767971376	--	GBP	0.9% p.a.	--	30/03/2012
I2 EUR	LU1725388273	5,000,000	EUR	0.8% p.a.	--	30/11/2017

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (LUX) - BB AFRICAN OPPORTUNITIES

For the purpose of calculation its overall risk exposure, the Sub-fund uses the Commitment Approach.

The Commitment Approach is a method to define the overall risk engagement of the sub-fund. Thereby, the derivative financial positions of the sub-fund are converted into the market values of equivalent positions of the underlying securities.

12. BELLEVUE FUNDS (LUX) - BB GLOBAL MACRO

INVESTOR PROFILE

The Sub-fund is only suitable for experienced investors, who have experience with volatile investments, in-depth knowledge of capital markets and specifically intend to profit from a globally well diversified portfolio containing various asset classes, and which are ready to accept certain market fluctuations and, therefore, dispose of a medium risk profile.

INVESTMENT OBJECTIVES AND POLICY

The investment objective of BB Global Macro is the achievement of a net positive return by using a global macro investment strategy and, hence, by investing in diligently selected and well diversified investments from different asset classes. The investment strategy intends to deliver to the investor a performance, which is above its reference index, the EUR 3 month-LIBOR.

The BB Global Macro invests in bonds, notes and other fixed- or variable interested debt instruments of all rating qualities, durations and currencies, in treasury notes, if issued and traded on international exchanges, in global equities, convertible bonds and bonds with warrants attached, in all other securities, which are officially admitted at a securities exchange, and in money market instruments.

To reduce the market risk, the sub-fund may temporarily hold up to 100% of its net assets in cash and/or in money market instruments.

In order to achieve an efficient management of its assets and within the applicable investment restrictions, the BB Global Macro may also apply derivative techniques and may use derivatives. The used financial derivative instruments include mainly options, futures, margin calls, forward contracts on a wide range of financial instruments and warrants on such financial instruments, without being limited to such financial derivative instruments.

The long-positions will be sufficiently liquid at any time in order to cover possible obligations of the sub-fund from its short-positions.

The sub-fund implements its investment policy by analysing the economic development and/or the volatility of specific markets. In order to achieve this investment objective, the sub-fund may use derivatives, which use the market volatilities as base value, namely "Volatility Swaps" and "Variance Swaps". With these derivatives, the sub-fund may under certain circumstances achieve a performance which is linked to the deviation between the implicit volatility and the real volatility at a certain point in time.

The sub-fund may also enter into credit risks with different issuers by investing into credit derivatives on indices or in basket of issuers.

The sub-fund may also invest in structured products, in particular in bonds or other securities, which performance is linked, e.g., to the performance of an index, of securities, of a basket of different securities or of an undertaking for collective investments in securities.

For risk diversification purposes, the sub-fund may also invest in financial derivative instruments, which have as base value commodity indices. An investment per such index is, however, limited to maximum 10% of the sub-funds' net assets.

The sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The BB Global Macro is denominated in EUR.

SPECIAL INVESTMENT RISKS

With regard to risk connected with investments in derivatives and contracts for differences, it is referred to the general risk chapter in 5.4.

The investment strategy and the risks of BB Global Macro differ from the investment strategies and risks of traditional funds, which invest exclusively in long-positions. BB Global Macro may in particular use derivative financial instruments to enter short-positions. In case that the values of such investments increase rather than decrease, the short-positions will have a negative performance effect on the value of the sub-fund and in extreme market situation, this may lead, theoretically, to unlimited losses of the sub-fund. In case of such an extreme market condition, the investors may achieve only a minimal or no performance at all or may lose all of their initial investment.

Whilst complying with the specified conditions and limits according to the law and as laid down by the CSSF, the Sub-fund is permitted to use techniques and instruments with a view to efficiently administer the investment portfolio, in particular also for hedging purposes.

The assets of BB Global Macro are subject to daily price fluctuations; as a result the value of the fund depends on the daily market value and consequently can rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets depends mainly on the general economic development as well as on company specific factors. It also depends on the supply and demand situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management AG.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

PERFORMANCE FEE

The asset manager of BB Global Macro is entitled to a performance-related management fee ("performance fee").

The claim to the performance fee arises when the percentage yield since the start of the calendar year is above that of the benchmark index, which is adjusted to the current market conditions at the end of each calendar year (last valuation day in December), (outperformance above the benchmark index) indicated below for each sub-fund and, at the same time, the net asset value per unit is above the high watermark (outperformance above the high watermark). Both conditions must be fulfilled cumulatively. The performance fee is 15% p.a. of the outperformance above the high watermark, respectively the outperformance above the relevant comparative index, whereby the lower percentage of both such determined out performances is used as the basis for calculating the performance fee.

High watermark: When the Sub-fund, respectively a share category is launched in some other currency to the invoicing currency, the high watermark is identical to the initial issue price. If the net asset value per share on the last valuation day of a subsequent calendar year is above the previous high watermark and the percentage yield in

the calendar year is above that of the benchmark index, the high watermark is set at the net asset value calculated before deducting the retained performance fee per share on the last valuation day of that calendar year. In all other cases, the high watermark remains unchanged.

The amount of the performance fee is recalculated on each valuation day, subject to the above-mentioned conditions on the basis of the outperformance since the beginning of the accounting year, and is deferred for the relevant unit classes. The newly calculated amount for the performance fee is compared on that valuation day with the provision on the previous valuation day. The provision formed on the previous day is suitably adjusted on the basis of the calculated difference between the newly calculated amount and this provision is adjusted upwards or downwards.

Performance fees calculated in accordance with the above conditions are paid to the investment manager after the end of the calendar year.

This ensures that a performance fee is only paid when the percentage yield of the sub-fund measured in the corresponding unit currency for an entire calendar year is above that of the benchmark index (outperformance above the benchmark index) and, at the same time, the net asset value per unit is above the high watermark (outperformance above the high watermark).

ICE Benchmark Administration Limited is the benchmark administrator of the EUR 3-month LIBOR and is listed in ESMA's official register.

FEES OF THE TARGET UCITS AND UCI

In case that the sub-fund may invest into units of other UCITS's and UCI's, it is pointed out that additional fees and expenses may be levied on the net assets of the sub-fund according to 4.6 of the prospectus, namely additional fees and expenses of the target funds for their custodians, central administrators, auditors, taxes and for other expenses, and such a double fee structure may occur.

The management fees of the target funds, in which the BB Global Macro may invest, may not exceed 2% p.a.

BB GLOBAL MACRO

Shares	ISIN code	Minimum investment	Currency of the shares	Administrati on fee	Performance Fee	Comparative Index	Initial issue date
I	LU0494762056	--	EUR	0.8% p.a.	15% p.a.	EUR 3 Month-Libor	31/03/2010
B	LU0494761835	--	EUR	1.4% p.a.	15% p.a.	EUR 3 Month-Libor	31/03/2010
AI	LU1525644909		EUR	0.8% p.a.	15% p.a.	EUR 3 Month-Libor	30/11/2016
AB	LU1325892591		EUR	1.4% p.a.	15% p.a.	EUR 3 Month-Libor	31/03/2016
HI CHF	LU0513479948	--	CHF	0.8% p.a.	15% p.a.	CHF 3 Month-Libor	31/05/2010
HB-CHF	LU0513479864	--	CHF	1.4% p.a.	15% p.a.	CHF 3 Month-Libor	31/05/2010
HI-GBP	LU0767971616	--	GBP	0.8% p.a.	15% p.a.	GBP 3-month Libor	30/03/2012
HI USD	LU1233583258	--	USD	0.8% p.a.	15% p.a.	USD 3-month Libor	10/08/2015
HB USD	LU1233584223	--	USD	1.4% p.a.	15% p.a.	USD 3-month Libor	02/07/2015
I2 EUR	LU1725388430	10,000,000	EUR	0.7% p.a.	15% p.a.	EUR 3 Month-Libor	30/11/2017
HI2 CHF	TBC	10'000'000	CHF	0.7% p.a.	15% p.a.	CHF 3 Month-Libor	Determined by the Board of Directors by circular resolution.
HI2 USD	TBC	10'000'000	USD	0.7% p.a.	15% p.a.	USD 3-month Libor	Determined by the Board of Directors by circular resolution.

RISK MANAGEMENT OF THE SUB-FUND BB GLOBAL MACRO:

In accordance with the provisions of the Law of 2010 and the provisions of CSSF Circular 11/512, after a thorough review by the Board of Directors of the Company, this sub-fund applies a risk management approach that ensures that all risks that may be relevant to this sub-fund can be determined.

Calculation of the overall risk/Global exposure

Part of the risk management process to be applied for this Sub-fund is the definition of the global exposure of the Sub-fund, which is determined and controlled via the absolute value at risk approach ("absolute VaR approach").

The VaR is calculated on the basis of a confidence level of 99%, and a holding period of 20 days.

The VaR of this sub-fund is calculated using the "Absolute VaR" approach.

This is based on the net asset value of the sub-fund and limited by a maximum VaR fixed by the Board of Directors of the Company after a thorough examination of the investments and the risk profile of this sub-fund.

The maximum VaR limit, which has thus been established for this sub-fund, is equal to 20% of the net asset value of the sub-fund.

BORROWING RATIO:

The leverage is defined by the relevant ESMA guidelines as the sum of the nominal values of the derivatives used in the sub-fund.

By definition this leads to conservative results since some derivatives used for hedging purposes are included in the calculation of leverage and thus lead to an increased leverage result.

Consequently, the leverage may under certain circumstances be significant but may not necessarily reflect the exact current risk of leverage to which an investor may be subject.

The expected leverage for this sub-fund may vary between 0% and 400% based on the net asset value of the sub-fund.

This estimate is based on historical data.

Under certain conditions (e.g. very low market volatility), the borrowing ratio of this sub-fund may also be higher.

13. BELLEVUE FUNDS (LUX) – BB EUROPE EQUITY MARKET NEUTRAL

INVESTOR PROFILE

The Sub-fund is only suitable for seasoned investors who have experience with volatile investments, in-depth knowledge of capital markets and specifically intend to profit from a market-neutral portfolio of mainly European equities, and who are prepared to accept a certain level of volatility and thus have a medium risk profile.

INVESTMENT OBJECTIVES AND POLICY

The investment objective of BB Europe Equity Market Neutral is to generate long-term capital gains in all market climates.

To achieve this, BB Europe Equity Market Neutral invests at least two thirds of its net assets – mainly through the use of derivative financial instruments – in a portfolio of carefully selected shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in recognised European countries.

In order to pursue the market-neutral strategy, BB Europe Equity Market Neutral will enter into long positions in attractive shares and other equity securities together with short positions in unattractive shares and other equity securities, generally through the use of cash-settled swaps. Under this strategy, the Sub-fund enters into a combination of individual swap agreements in which the performance of long or short equity positions is exchanged against financing, generally based on a recognised money market rate.

BB Europe Equity Market Neutral will therefore hold up to 150% of its net assets in long positions via shares and other equity securities issued by companies as well as via derivative financial instruments, and up to 150% of its net assets in short positions via cash-settled derivative financial instruments.

In order to implement its market-neutral strategy and achieve an efficient management of its assets within the applicable investment restrictions, BB Europe Equity Market Neutral also intends to apply derivative techniques or use derivatives. The financial derivative instruments used include mainly swaps, options, futures, contracts for difference, forward contracts on a wide range of financial instruments and options on such financial instruments, but are not limited to such financial derivative instruments.

The obligations entered into through the use of derivative financial instruments are covered by liquid investments such as fixed or floating-rate securities, debt securities and claims (including zero bonds) with good credit ratings, money market instruments, cash and cash equivalents.

To reduce the market risk, the sub-fund may temporarily hold up to 100% of its net assets in cash and/or in money market instruments.

The long-positions will be sufficiently liquid at any time in order to cover possible obligations of the Sub-fund from its short-positions.

The Sub-fund may also invest in structured products, in particular in bonds or other securities, which performance is linked, e.g., to the performance of a financial index, of securities, of a basket of different securities or of an undertaking for collective investments in securities. The underlyings of these structured products will fulfil the conditions of Article 41 of the Law of 2010.

The Sub-fund may also invest up to 10% of its net assets in units of UCITS and other UCIs.

The total return swaps in which the sub-fund invests are expected to represent 5% to 10% of the sub-fund's net asset value.

BB Europe Equity Market Neutral is denominated in EUR.

SPECIAL INVESTMENT RISKS

With regard to risk connected with investments in derivatives and contracts for differences, it is referred to the general risk chapter in 5.4.

The investment strategy and the risks of BB Europe Equity Market Neutral differ from those of traditional funds, which invest exclusively in long positions. In particular, BB Europe Equity Market Neutral uses derivative financial instruments to enter into short positions. In case that the values of such investments increase rather than decrease, the short-positions will have a negative performance effect on the value of the sub-fund and in extreme market situation, this may lead, theoretically, to unlimited losses of the Sub-fund. In case of such an extreme market condition, the investors may achieve only a minimal or no performance at all or may lose all of their initial investment.

Whilst complying with the specified conditions and limits according to the law and as laid down by the CSSF, the sub-fund is permitted to use techniques and instruments with a view to efficiently administer the investment portfolio, in particular also for hedging purposes.

The assets of BB Europe Equity Market Neutral are subject to daily price fluctuations; as a result, the value of the fund depends on the daily stock market value and may therefore rise or fall. Consequently, there is a risk that an investor may not get back the amount originally invested. The value of the assets largely depends on general economic developments as well as company-specific factors. It also depends on the supply and demand

situation in the stock market, which in turn is heavily influenced by the expectations of market participants.

INVESTMENT MANAGER

Bellevue Asset Management Ltd.

SUB-INVESTMENT MANAGER

StarCapital AG, an *Aktiengesellschaft* (public limited company) with its registered office at Kronberger Strasse 45, 61440 Oberursel (Taunus), Germany, is regulated by BaFin.

StarCapital AG has been appointed by Bellevue Asset Management AG as sub-investment manager under a sub-asset management agreement and will be remunerated by the Sub-fund out of the Management Fee.

ISSUING THE SHARES

The Board of Directors may decide at any time the issuance of one or several new share classes.

The Board of Directors may decide at any time the issuance of one or several new share classes. The initial issuance date of such shares classes will be decided by the Board of Directors after having received CSSF approval based on an updated Prospectus version.

SUBMITTING THE ORDERS

Subscription: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Redemption: At the latest at 15.00 hours on the business day before the day on which the net asset value is determined.

Switching: The earliest time between the two affected Sub-funds.

PERFORMANCE FEE

The Sub-Investment Manager of BB Europe Equity Market Neutral is entitled to receive a performance fee at the end of each calendar year ("**Performance Fee**") if the following conditions are met.

They are entitled to a Performance Fee whenever at the end of a five-year period there is both an Outperformance above the Benchmark Index and an Outperformance above the High Watermark at the end of the previous five calendar years.

If the share class for which the Performance Fee is calculated has existed for less than five years, only the period since the initial issue date is taken into account for the calculation of the Performance Fee. Accordingly, the initial reference value from which the Outperformance

above the High Watermark is calculated is the initial issue price.

"**Outperformance above the benchmark**" means that the Sub-Fund achieves a higher return than the comparative Index listed in the table below. "**Outperformance above the High Watermark**" means that the highest Net Asset Value at which a Performance Fee was paid has been exceeded.

The Performance Fee is 15% p.a. of the Outperformance above the High Watermark or the Outperformance above the relevant Benchmark Index, whereby the lower percentage of the two outperformances determined in this way is used as the basis for calculating the Performance Fee. In total, the Performance Fee will not exceed 5% of the Company's average net asset value in the calendar year, calculated based on the values at the end of each month.

The amount of the Performance Fee is recalculated and accrued for each share class on each valuation day, subject to the above-mentioned conditions on the basis of the outperformance since the beginning of the accounting year. The newly calculated amount for the Performance Fee is compared on that valuation day with the accrual on the previous valuation day. The accrual formed on the previous day is suitably adjusted on the basis of the calculated difference between the newly calculated amount and this accrual is adjusted upwards or downwards.

ICE Benchmark Administration Limited is the benchmark administrator of the EUR 3-month LIBOR and is listed in ESMA's official register.

FEEES OF THE TARGET UCITS AND UCI

If the sub-fund is permitted to invest in shares of other UCITS and UCIs, it should be noted that additional fees and expenses may be levied on the net assets of the sub-fund according to section 4.6, namely additional fees and expenses of the target funds for their central administrators, custodians, auditors, taxes and for other expenses. As such, double fees may be charged.

The management fees of the target funds in which BB Europe Equity Market Neutral may invest may not exceed 2% p.a.

BB EUROPE EQUITY MARKET NEUTRAL

Share s	ISIN	Minimum investment	Currency of the shares	Managemen t fee	Performan ce Fee	Comparative Index	Initial issue date
I	LU1947777014	--	EUR	0.8% p.a.	15% p.a.	EUR 3 Month-Libor	30/04/2019
AI	LU1947777105	--	EUR	0.8% p.a.	15% p.a.	EUR 3 Month-Libor	30/04/2019
B	LU1947777287	--	EUR	1.4% p.a.	15% p.a.	EUR 3 Month-Libor	30/04/2019
I2	LU1947777360	5,000,000	EUR	0.7% p.a.	15% p.a.	EUR 3 Month-Libor	30/04/2019
HI CHF	LU1947777444	--	CHF	0.8% p.a.	15% p.a.	CHF 3 Month-Libor	30/04/2019
HB-CHF	LU1947777527	--	CHF	1.4% p.a.	15% p.a.	CHF 3 Month-Libor	30/04/2019
HI2 CHF	LU1947777790	5,000,000	CHF	0.7% p.a.	15% p.a.	CHF 3 Month-Libor	30/04/2019

RISK MANAGEMENT OF THE SUB-FUND BELLEVUE FUNDS (LUX) - BB EUROPE EQUITY MARKET NEUTRAL

In accordance with the provisions of the Law of 2010 and CSSF Circular 11/512, after a thorough review by the Board of Directors of the Company, this sub-fund applies a risk management approach that ensures that all risks that may be relevant to this sub-fund can be determined.

CALCULATION OF THE OVERALL RISK/GLOBAL EXPOSURE

Part of the risk management process to be applied for this sub-fund is the definition of the global exposure of the sub-fund, which is determined and controlled via the absolute value at risk approach ("absolute VaR approach").

The VaR is calculated on the basis of a confidence level of 99%, and a holding period of 20 days.

The VaR of this sub-fund is calculated using the "Absolute VaR" approach.

This is based on the net asset value of the sub-fund and limited by a maximum VaR fixed by the Board of Directors of the Company after a thorough examination of the investments and the risk profile of this sub-fund.

The maximum VaR limit, which has thus been established for this sub-fund, is equal to 20% of the net asset value of the sub-fund.

BORROWING RATIO:

The leverage is defined by the relevant ESMA guidelines as the sum of the nominal values of the derivatives used in the sub-fund.

By definition this leads to conservative results since some derivatives used for investment and hedging purposes are included in the calculation of leverage and thus lead to an increased leverage result.

Consequently, the leverage may under certain circumstances be significant but may not necessarily reflect the exact current risk of leverage to which an investor may be subject.

The expected leverage for this sub-fund may vary between 0% and 300% based on the net asset value of the sub-fund. An exposure of up to 300% stems from the Total Return Swap and the underlying long and short positions, whereas the remaining exposure may be created through the use of Derivatives in which the sub-fund may invest in line with its investment policy.

This estimate is based on historical data.

Under certain conditions (e.g. very low market volatility), the leverage of this sub-fund may also be higher.



For further information, please contact:
www.bellevue.ch

Tel. +41 44 267 67 00
E-Mail: info@bellevue.ch